WO2008113114A1 - Body fluid supplement compositions and their use in subjects undergoing medical treatment - Google Patents
Body fluid supplement compositions and their use in subjects undergoing medical treatment Download PDFInfo
- Publication number
- WO2008113114A1 WO2008113114A1 PCT/AU2008/000371 AU2008000371W WO2008113114A1 WO 2008113114 A1 WO2008113114 A1 WO 2008113114A1 AU 2008000371 W AU2008000371 W AU 2008000371W WO 2008113114 A1 WO2008113114 A1 WO 2008113114A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- meq
- per litre
- ions
- composition
- vitamin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 288
- 238000011282 treatment Methods 0.000 title claims abstract description 27
- 239000013589 supplement Substances 0.000 title description 11
- 210000001124 body fluid Anatomy 0.000 title description 6
- 239000010839 body fluid Substances 0.000 title description 6
- 235000013361 beverage Nutrition 0.000 claims abstract description 128
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 94
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 47
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 47
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 47
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 47
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 45
- -1 citrate ions Chemical class 0.000 claims abstract description 44
- 229910001414 potassium ion Inorganic materials 0.000 claims abstract description 42
- 229910001415 sodium ion Inorganic materials 0.000 claims abstract description 42
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims abstract description 41
- 229910001425 magnesium ion Inorganic materials 0.000 claims abstract description 41
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 76
- 238000000034 method Methods 0.000 claims description 69
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 38
- 229930003268 Vitamin C Natural products 0.000 claims description 38
- 235000019154 vitamin C Nutrition 0.000 claims description 38
- 239000011718 vitamin C Substances 0.000 claims description 38
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 33
- 239000008103 glucose Substances 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 17
- 239000008187 granular material Substances 0.000 claims description 16
- 238000011275 oncology therapy Methods 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 14
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 235000012054 meals Nutrition 0.000 claims description 14
- 238000002512 chemotherapy Methods 0.000 claims description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 7
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 7
- 239000001103 potassium chloride Substances 0.000 claims description 7
- 235000011164 potassium chloride Nutrition 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 238000001959 radiotherapy Methods 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 229960000999 sodium citrate dihydrate Drugs 0.000 claims description 6
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 150000002772 monosaccharides Chemical class 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 238000001815 biotherapy Methods 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 230000001502 supplementing effect Effects 0.000 claims description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 208000024891 symptom Diseases 0.000 description 25
- 235000013334 alcoholic beverage Nutrition 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 14
- 239000012141 concentrate Substances 0.000 description 13
- 208000008445 altitude sickness Diseases 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 229910019142 PO4 Inorganic materials 0.000 description 10
- 208000005156 Dehydration Diseases 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000018044 dehydration Effects 0.000 description 9
- 238000006297 dehydration reaction Methods 0.000 description 9
- 206010047700 Vomiting Diseases 0.000 description 8
- 230000035622 drinking Effects 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 230000008673 vomiting Effects 0.000 description 7
- 239000003792 electrolyte Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 208000007101 Muscle Cramp Diseases 0.000 description 5
- 229960003390 magnesium sulfate Drugs 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009532 heart rate measurement Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 239000004337 magnesium citrate Substances 0.000 description 2
- 229960005336 magnesium citrate Drugs 0.000 description 2
- 235000002538 magnesium citrate Nutrition 0.000 description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 2
- 239000004137 magnesium phosphate Substances 0.000 description 2
- 229960002261 magnesium phosphate Drugs 0.000 description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 2
- 235000010994 magnesium phosphates Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000023409 throat pain Diseases 0.000 description 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229940023356 vitamin b6 10 mg Drugs 0.000 description 2
- 229940089133 vitamin b6 5 mg Drugs 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000012171 hot beverage Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000018944 leg cramp Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a body fluid supplement composition and uses thereof.
- the human body In order to maintain its physical capabilities, the human body requires optimal amounts of water, electrolytes, carbohydrate and a range of other minerals/nutrients, Where these optimal amounts are disturbed, physical and mental capabilities may be compromised.
- the present inventor has developed a body fluid supplement composition which, surprisingly, finds utility in treating a number of ailments and conditions.
- the present invention provides an aqueous beverage composition comprising the following components: (i) sodium ions; (ii) potassium ions; (iii) magnesium ions; (iv) phosphate ions;
- the composition may consist essentially of the above components.
- the sodium ions may be present in an amount between about 10 meq. and about 35 meq. per litre of the beverage composition.
- the potassium ions may be present in an amount between about 5 meq. and about 30 meq. per litre of the beverage composition.
- the magnesium ions may be present in an amount between about 5 meq. and about 25 meq. per litre of the beverage composition.
- the phosphate ions may be present in an amount between about 1 meq. and about 55 meq. per litre of the beverage composition.
- the citrate ions may be present in an amount between about 0.1 meq. and about 45 meq. per litre of the beverage composition.
- the vitamin B6 may be present in an amount between about 0.1 mg and about 200 mg per litre of the beverage composition.
- the carbohydrate may be present in an amount between about 2% and about 20% by weight of the total beverage composition (w/w).
- the carbohydrate may be a monosaccharide or a disaccharide, or a mixture thereof.
- the carbohydrate is a monosaccharide, for example glucose, fructose, mannose or galactose, or a mixture thereof.
- the sodium ions may be present by inclusion of sodium phosphate, sodium chloride, sodium citrate, sodium sulfate or any combination thereof in the beverage composition.
- the potassium ions may be present by inclusion of potassium chloride, potassium citrate, potassium phosphate, potassium sulfate or any combination thereof in the beverage composition.
- the magnesium ions may be present by inclusion of magnesium sulfate, magnesium phosphate, magnesium citrate, magnesium • chloride or any combination thereof in the beverage composition.
- the phosphate ions may be present by inclusion of sodium phosphate, potassium phosphate, magnesium phosphate or any combination thereof in the beverage composition.
- the citrate ions may be present by inclusion of sodium citrate, potassium citrate, magnesium citrate or any combination thereof in the beverage composition.
- the composition may further comprise vitamin C.
- the vitamin C may be present in an amount between about 30 mg and about 2000 mg per litre of the beverage composition.
- the beverage composition may be isotonic.
- the beverage composition may have a pH in the range of about 3.0 to about 5.0, or from about 3.0 to about 4.5, or from about 3.0 to about 4.0, or from about 3.2 to about 4.0, or from about 3.2 to about 3.8, or from about 3.4 to about 3.8.
- the composition may be dried to form, for example, a powder, granules or tablets.
- the present invention provides a concentrate for use in preparing an aqueous beverage composition, the concentrate comprising a mixture of components in amounts such that when constituted with water or an appropriate liquid to form the aqueous beverage composition, the following proportions of the components are obtained: (i) sodium ions in an amount between about 10 meq. and about 35 meq. per litre of the beverage composition.
- magnesium ions in an amount between about 5 meq. and about 25 meq. per litre of the beverage composition.
- citrate ions in an amount between about 0.1 meq. and about 45 meq. per litre of the beverage composition.
- vitamin B6 in an amount between about 0.1 mg and 200 mg per litre of the beverage composition;
- the concentrate may be in the form of a powder, granules or tablets.
- the present invention provides a process for the manufacture of an aqueous beverage composition, wherein the concentrate of the second aspect is mixed with a quantity of water, or an appropriate liquid, sufficient to provide a solution suitable for consumption by drinking.
- the present invention provides an aqueous beverage composition whenever prepared by the process of the third aspect.
- the beverage composition of the invention comprises between about 12 meq. and about 32 meq. per litre of sodium ions, between about 10 meq. and about 25 meq. per litre of potassium ions, between about 7 meq. and about 20 meq. per litre of magnesium ions, between about 5 meq. and 25 meq. per litre of phosphate ions, between 1 and 15 meq. per litre of citrate ions; between 20 mg and 40 mg per litre of vitamin B6 and between 10% and 20% glucose (w/w).
- This composition may additionally comprise vitamin C in an amount between • about 250 mg and about 1200 mg per litre.
- the composition may have a pH of about 3.4 to 3.8.
- the beverage composition of the invention comprises about 22 meq. per litre of sodium ions, about 17 meq. per litre of potassium ions, about 13 meq. per litre of magnesium ions, about 10 meq. per litre of phosphate ions, about 5 meq. per litre of citrate ions, about 20 mg per litre, of vitamin B6 and about 16% glucose (w/w).
- the composition may have a pH of about 3.4 to 3.8.
- the beverage composition of the invention comprises about 22 meq. per litre of sodium ions, about 17 meq. per litre of potassium ions, about 13 meq. per litre of magnesium ions, about 10 meq. per litre of phosphate ions, about 5 meq. per litre of citrate ions, 20 mg per litre of vitamin B6, 16% glucose (w/w), and 480 mg per litre of vitamin C.
- the composition may have a pH of about 3.4 to 3.8.
- the beverage composition of the invention comprises about 22 meq. per litre of sodium ions, about 17 meq. per litre of potassium ions, about 13 meq. per litre of magnesium ions, about 10 meq. per litre of phosphate ions, about 5 meq. per litre of citrate ions, about 40 mg per litre of vitamin B6, about 16% glucose (w/w), and 1000 mg per litre of vitamin C.
- the composition may have a pH of about 3.4 to 3.8.
- the beverage composition of the invention comprises about 22 meq. per litre of sodium ions, about 17 meq. per litre of potassium ions, about 13 meq. per litre of magnesium ions, about 10 meq. per litre of phosphate ions, about 5 meq. per litre of citrate ions, about 40 mg per litre of vitamin B6, about 16% glucose (w/w), and about 480 mg per litre of vitamin C.
- the composition may have a pH of about 3.4 to 3.8.
- the beverage composition of the invention comprises between about
- the pH of this composition may be about 3.4 to about 3.8.
- the beverage composition of the invention comprises between about 17 meq. and about 27 meq. per litre of sodium ions, between about 13 meq. and about 21 meq. per litre of potassium ions, between about 13 meq. and about 21 meq. per litre of magnesium ions, between about 11 meq. and about 17 meq. per litre of phosphate ions, between about 0.25 meq. and about 5 meq. per litre of citrate ions, between about 100 mg and about 200 mg per litre of vitamin C, between about 20 and 60 mg per litre of vitamin B6, and between about 14% and about 18% glucose (w/w).
- the pH of this composition maybe about 3.4 to about 3.8.
- the beverage composition of the invention comprises about 22 meq. per litre of sodium ions, about 17 meq. per litre of potassium ions, about 17 meq. per litre of magnesium ions, about 15 meq. per litre of phosphate ions, about 1 meq. per litre of citrate ions, about 160 mg per litre of vitamin C, about 40 mg per litre of vitamin B6, and about 16% glucose (w/w).
- the pH of this composition may be about 3.4 to about 3.8.
- the beverage composition of the invention is prepared by adding: sodium phosphate monobasic (400 to 550 mg), sodium chloride (60 to 80 mg), sodium citrate dihydrate (100 to 140 mg), potassium chloride (270 to 350 mg), magnesium sulfate (230 to 290 mg), vitamin C (30 to 50 mg), vitamin B6 (5 to 15 mg) and glucose (about 35 to 45 grams), to 250 mL of water, or other suitable liquid.
- the pH of this composition may be about 3.4 to about 3.8.
- the beverage composition of the invention is prepared by adding: sodium phosphate monobasic (470.0 mg), sodium chloride (69.0 mg), sodium citrate dihydrate (120.0 mg), potassium chloride (318.0 mg), magnesium sulfate (260.0 mg), vitamin C (40.0 mg), vitamin B6 (10.0 mg) and glucose (about 40 grams), to 250 mL of water, or other suitable liquid.
- the pH of this composition may be about 3.4 to about 3.8.
- the present invention provides a method of reducing or preventing one or more symptoms of altitude sickness in a subject, said method comprising administration to said subject of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects.
- the amount of vitamin B6 present in- the composition used in the fifteenth aspect may be between about 10 mg and about 50 mg per litre of the beverage composition.
- the present invention provides a method of reducing or preventing one or more symptoms of dehydration in a subject, said method comprising administration to said subject of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects. . '
- the amount of vitamin B6 present in the composition used in the sixteenth aspect may be between about 2 mg and about 10 mg per litre of the beverage composition. In one embodiment, the amount of vitamin B6 present in the composition used in the sixteenth aspect may be about 5 mg per litre of the beverage composition.
- the present invention provides a method of reducing the blood alcohol concentration in a subject, said method comprising administration to said subject of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects.
- the method may comprise the step of administering the composition to the subject before the subject drinks a first alcoholic drink.
- the method may further comprise the step of administering the composition to the subject after the subject drinks a first alcoholic drink, and prior to the subject drinking a second alcoholic drink.
- the method may further comprise the step of administering the composition to the subject after each subsequent alcoholic drink consumed after the first alcoholic drink.
- the amount of vitamin B6 present in the composition used in the seventeenth aspect may be between about 10 mg and about 25 mg per litre of the beverage composition.
- the present invention provides a method for supplementing the meals or replacing the meals of a subject undergoing medical treatment, said method comprising administration to said subject of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects.
- the medical treatment may be any type of medical treatment or intervention that causes a reduction in the appetite of the subject.
- the medical treatment may be a surgical procedure such as an appendix operation, or a treatment in which anaesthetic or pain killers are used, or alternatively a treatment that results in diarrhea in the subject, or a treatment that involves drugs that suppress appetite and/or cause nausea.
- the medical treatment may be cancer therapy.
- the cancer therapy may be surgery, chemotherapy, radiotherapy, hormone therapy or immunotherapy.
- the subject may be a human.
- the present invention provides a method for enhancing the response of a subject to cancer therapy, said method comprising administration to said subject of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects.
- the present invention provides a method for the treatment of cancer in a subject in need of said treatment, said method comprising administering to said subject an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects, together with chemotherapy and/or radiotherapy and/or biological therapy.
- the present invention provides the use of the composition of the first, second, fourth or fifth to fourteenth aspects as an adjunct to cancer therapy.
- the present invention provides a method for reducing or preventing cramps, said method comprising administration of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects.
- the composition may be given in the form of a beverage composition, or alternatively in the form of a concentrate as defined in the second aspect.
- compositions of the first or fifth to fourteenth aspects may be in the form of a concentrate that is used for preparing an aqueous beverage composition, the concentrate comprising a mixture of components in amounts such that when constituted with water or an appropriate liquid to form the aqueous beverage composition, the proportions of the components are those given in the first or fifth to fourteenth aspects.
- carbohydrate refers to monosaccharides, oligosaccharides, complex polysaccharides, or mixtures thereof.
- the term “comprising” means “including principally, but not necessarily solely”. Furthermore, variations of the word “comprising”, such as “comprise” and “comprises”, have correspondingly varied meanings.
- the term “effective amount”, includes within its meaning an amount of the composition that provides the desired effect. The exact amount required will vary from subject to subject depending on factors such as the subject's general health, age and the condition for which they are receiving treatment.
- standard drink(s) refers to a drink that contains about 10 grams of alcohol.
- the terms “reduction” and “reducing” in the context of “one or more symptoms” encompass the elimination or substantial elimination of a symptom, the arresting of a symptom such that the symptom does not worsen, and the amelioration, including partial amelioration, of a symptom.
- the elimination, substantial elimination, arresting or amelioration need not be of all symptoms of the condition, but maybe of one or more symptoms thereof.
- Figure 1 shows the blood alcohol concentrations (mg/L) after a given time in individuals consuming a combination of (i) alcohol and a composition in accordance with the invention (composition X, — ⁇ — ⁇ ), and (ii) alcohol and water ( -*— ).
- Figure 2 shows a heart rate measurement performed every 10 minutes in individuals consuming a combination of (i) alcohol and a composition in accordance with the invention (composition X, ⁇ ), and (ii) alcohol and water (— «—).
- the present invention relates to an aqueous beverage composition
- an aqueous beverage composition comprising sodium ions, potassium ions, magnesium ions, phosphate ions, citrate ions, vitamin B6 and carbohydrate.
- the present invention also relates to a concentrate for use in preparing an aqueous beverage composition, the concentrate comprising a mixture of components in amounts such that when constituted with water, or an appropriate liquid, to form the aqueous beverage composition, specific proportions of the components are obtained.
- the present invention also relates to a process for the manufacture of an aqueous beverage composition, wherein a concentrate is mixed with a quantity of water, or an appropriate liquid, sufficient to provide a solution suitable for consumption by drinking, and a beverage composition obtained by such a process.
- the amount of sodium ions present in the aqueous beverage composition may be between about 10 meq. and about 35 meq. per litre of the beverage composition, or between about 12 meq. and about 35 meq., or between about 14 meq. and about 35 meq., or between about 16 meq. and about 35 meq., or between about 18 meq. and about 35 meq., or between about 20 meq. and about 35 meq., or between about 22 meq. and about 35 meq., or between about 24 meq. and about 35 meq., or between about 26 meq. and about 35 meq., or between about 28 meq. and about 35 meq., or between about 10 meq. and about 32 meq., or between about 10 meq.
- the amount of sodium ions present in the beverage composition may be 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 meq. per litre of the beverage composition.
- the amount of potassium ions present in the aqueous beverage composition may be between about 5 meq. and about 30 meq. per litre of the beverage composition, or between about 7 meq. and about 30 meq., or between about 9 meq. and about 30 meq., or between about 11 meq. and about 30 meq., or between about 13 meq. and about 30 meq., or between about 15 meq. and about 30 meq., or between about 17 meq. and about 30 meq., or between about 19 meq. and about 30 meq., or between about 21 meq. and about 30 meq., or between about 23 meq. and about 30 meq., or between about 25 meq. and about 30 meq., or between about 5 meq.
- the amount of potassium ions present in the beverage composition may be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 meq. per litre of the beverage composition.
- the amount of magnesium ions present in the composition may be between about 5 meq. and about 25 meq. per litre of the beverage composition, or between about 5 meq. and about 23 meq., or between about 5 meq. and about 21 meq., or between about 5 meq. and about 21 meq., or between about 5 meq. and about 19 meq., or between about 5 meq. and about 17 meq., or between about 5 meq. and about 16 meq., or between about 5 meq. and about 15 meq., or between about 5 meq: and about 14 meq., or between about 6 meq. and about 25 meq, or between about 7 meq. and about 25 meq, or between about 9 meq. and about 25 meq., or between about 11 meq.
- the amount of magnesium ions present in the beverage composition may be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 meq. per litre of the beverage composition.
- the phosphate ions in the beverage composition are present as mixtures of PO 4 3" , H 2 PO 4 " and HPO 4 2" , the relative concentrations of which are pH dependent.
- the term “phosphate” is understood to encompass PO 4 3" , H 2 PO 4 " and HPO 4 2" , unless otherwise specifically stated.
- H 2 PO 4 " is by far the most abundant species in solution, whereas at pH 7.4, HPO 4 2" is the most abundant species.
- the amount of phosphate ioris present in the composition may be between about 1 meq. and about 55 meq., or between about 2 meq. and about 55 meq., or between about 4 meq. and about 55 meq., or between about 6 meq. and about 55 meq., or between about 8 meq. and about 55 meq., or between about 10 meq. and about 55 meq., or between about 12 meq. and about 55 meq., or between about 14 meq. and about 55 meq., or between about 16 meq. and about 55 meq k , or between about 18 meq. and about 55 meq., or between about 20 meq. and about 55 meq., or between about 22 meq. and about 55 meq., or between about 24 meq.
- the amount of phosphate ions present in the beverage is not limited to the amount of phosphate ions present in the beverage
- 5 composition may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54 or 55 meq. per litre of the beverage composition.
- the amount of phosphate ions in the beverage composition may be between about 1 meq. and about 30 meq., or betweeno about 3 meq. and about 28 meq., or between about 5 meq. and about 25 meq., or between about 6 meq. and about 22 meq., or between about or between about 8 meq. and about 21 meq., or between about 9 meq. and about 20'meq., or between about 10 meq. and about 20 meq, or between about 12 meq., and about 18 meq., or about 10 meq., or about 15 meq. per litre of the beverage composition.
- the amount of phosphate ions present in the beverage composition (as either PO 4 3" ,
- H 2 PO 4 " , HPO 4 2" may be between about 0.25 and about 3.5, or between about 0.5 and about 3.25, or between about 0.5 and about 3, or between about 0.5 and about 2.5, or between about 0.5 and about 2.25, or between about 0.5 and about 2, or between about 0.75 and about 1.75, or about 1.5, or about 1, grams per litre of the beverage composition.
- the citrate ions in the beverage composition are present as mixtures of C 6 H 7 O 7 " ,
- citrate is understood to encompass C 6 H 7 O 7 " , C 6 H 6 O 7 2" and C 6 HsO 7 3" , unless otherwise specifically stated.
- C 6 H 7 O 7 " is the most abundant species. 5
- the amount of citrate ions present in the composition may be between about 0.1 meq. and about 45 meq., or between about 0.5 meq. and about 45 meq., or between about 1 meq. and about 45 meq., or between about 2 meq. and about 45 meq., or between about 4 meq. and about 45 meq., or between about 6 meq.
- the amount of citrate ions present in the beverage composition may be 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,- 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, or 45 meq. per litre of the beverage composition.
- the amount of citrate ions in the beverage composition (as C 6 H 7 O 7 " ) may be between about 0.25 meq. and about 15 meq., or between about 0.5 meq. and about 15 meq., or between about 1 meq. and about 13 meq., or between about 1 meq. and about 12 meq., or between about 1 meq. and about 10 meq., or between
- the amount of citrate ions present in the beverage composition may be between about 0.1 and about 3.5, or between about 0.1 and about 3.25, or between about 0.1 and about 3, or between about 0.1 and about 2.5, or between about 0.1 and about 2.25, or between about 0.1 and about 2, or between about 1 and about 2.5, or between about 1 and about 2.25, or between about 1.25 and about 2.25, or between about 1.5 and about 2, or between about 0.1 and about 1, or between about 0.15 and about 0.75, or between about. 0.1 and about 0.5, grams per litre of the beverage composition.
- the amount of vitamin B6 present in the composition may be between about 0.1 mg and 200 mg per litre of the beverage composition, or between about 0.1 mg and 180 mg, or between about 0.1 mg and about 170 mg, or between about 0.1 mg and about 160 mg, oro between about 0.1 mg and about 150 mg, or between about 0.1 mg and about 140 mg, or between about 0.1 mg and about 130 mg, or between about 0.1 mg and about 120 mg, or between about 0.1 mg and about 110 mg, or between about 0.1 mg and about 100 mg, or between about 0.1 mg and about 90 mg, or between about 0.1 mg and about 80 mg, or between about 0.1 mg and about 70 mg, or between about 0.1 mg and about 60 mg, or5 between about 0.1 mg and about 50 mg, or between about 0.1 and about 45 mg, or between about 1 and about 200 mg, or between about 5 mg and about 200 mg, or between about 10 mg and about 200 mg, or between about 20 mg and about 200 mg, or between about 30 mg and about 200 mg, or between about 40 mg and about 200 mg, or
- the amount of vitamin B6 per litre of the beverage composition may be 0.1, 0.5, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190 or 200 mg.
- the carbohydrate included in the beverage compositions may be present in an amount between about 2% and about 20% by weight of the beverage composition, or between about 2% and about 19%, or between about 2% and about 18%, or between about 2% and about 17%, or between about 2% and about 16%, or between about 2% and about 13%, or between about 2% and about 12%, or between about 2% and about 11%, or between about 2% and about 10%, or between about 7% and about 20%, or between about 9 % and about 20%, or between about 10% and about 20%, or between about 11% and about 20%, or between about 12% and about 20%, or between about 13% and about 20%, or between about 14% and about 20%, or between about 14% and about 18%, or between about 15% and about 18% or between about 15% and about 17%.
- the carbohydrate is present in 16% by weight of the total beverage composition.
- the meq. per litre ratio of sodium ions to potassium ions may be between about 1.0 and about 1.8, or between about 1.1 and about 1.75, or between about 1.1 and about 1.7, or between about 1.15 and about 1.6, or between about 1.2 and about 1.55, or between about 1.2 and about 1.5, or between about 1.2 and about 1.45, or between about 1.2 and about 1.4, or between about 1.25 and about 1.35, or about 1.3.
- the beverage composition of the first aspect may be prepared by simply adding the relevant components to an aqueous medium with or without agitation. The resultant solution may then be consumed by drinking.
- the beverage composition of the first aspect may be dehydrated to provide a dry mixture of the composition. This dry mixture, either as powder, granules or tablets, can be later re-dissolved in an appropriate amount of water, or other appropriate liquid, to re-establish the drinkable beverage composition.
- the concentrate of the second aspect may be prepared by simply mixing the relevant components together in the necessary amounts.
- the concentrate may be prepared in the form of a powder, granules or tablets, which may be reconstituted for use by the addition of water, or any other appropriate liquid.
- the reconstitution is made with appropriate amounts of water/liquid to ensure that the beverage obtained comprises the components in the proportions given in the second aspect.
- the composition may be solubilised in water/liquid and then frozen to provide "ice blocks".
- the beverage composition of the invention provides an advantage over many other currently available body fluid supplement beverages in that it has improved palatability.
- the beverage composition has a taste that is similar to apple juice.
- the beverage composition of the invention comprises between about 10 meq. and about 32 meq. per litre -of sodium ions, between about 10 meq. and about 25 meq. per litre of potassium ions, between about 8 meq. and about 25 meq. per litre of magnesium ions, between about 10 meq. and about 50 meq. per litre of phosphate ions, between about 0.5 meq. and about 30 meq. per litre of citrate ions, between about 10 mg and about 60 mg per litre of vitamin B6 and between about 10% and 20% glucose (w/w).
- This composition may additionally ⁇ comprise vitamin C in an amount between about 100 mg and about 1500 mg per litre.
- the composition may be in the form of a powder or granules, or may be in the form of an aqueous solution.
- the beverage composition of the invention comprises between about 12 meq. and about 32 meq. per litre of sodium ions, between about 10 meq. and about 25 meq. per litre of potassium ions, between about 7 meq. and about 20 meq. per litre of magnesium ions, between about 5 meq. and about 25 meq. per litre of phosphate ions, between about 1 meq. and about 15 meq. per litre of citrate ions, between about 20 mg and about 40 mg per litre of vitamin B6 and between about 10% and 20% glucose (w/w).
- compositions may additionally comprise vitamin C in an amount between about 250 mg and about 1200 mg per litre.
- the composition in solution may have a pH of about 3.4 to 3.8.
- the composition may be in the form of a powder or granules, or may be in the form of an aqueous solution.
- the beverage composition of the invention comprises about
- the composition in solution may have a pH of about 3.4 to 3.8.
- the composition may be in the form of a powder or granules, or may be in the form of an aqueous solution.
- the beverage composition of the invention comprises about
- the composition in solution may have a pH of about 3.4 to 3.8.
- the composition may be in the form of a powder or granules, or may be in the form of an aqueous solution.
- the beverage composition of the invention comprises about 22 meq. per litre of sodium ions, about 17 meq. per litre of potassium ions, about 13 meq.
- the composition in solution may have a pH of about 3.4 to 3.8.
- the composition may be in the form of a powder or granules, or may be in the form of an aqueous solution.
- the beverage composition of the invention comprises about 22 meq. per litre of sodium ions, about 17 meq. per litre of potassium ions, about 13 meq. per litre of magnesium ions, about 10 meq. per litre of phosphate ions, about 5 meq. per litre of citrate ions, about 40 mg per litre of vitamin B6, about 16% glucose (w/w), and about 480 mg per litre of vitamin C.
- the composition in solution may have a pH of about 3.4 to 3.8.
- the composition may be in the form of a powder or granules, or may be in the form of an aqueous solution.
- the beverage composition of the invention comprises between about 12 meq. and about 32 meq.
- the pH of the composition in solution may be about 3.4 to about 3.8.
- the composition may be in the form of a powder or granules, or may be in the form of an aqueous solution.
- the beverage composition of the invention comprises between about 17 meq. and about 27 meq. per litre of sodium ions, between about 13 meq. and about 21 meq. per litre of potassium ions, between about 13 meq. and about 21 meq. per litre of magnesium ions, between about 11 meq. and about 17 meq. per litre of phosphate ions, between about 0.25 meq. and about 5 meq. per litre of citrate ions between about 100 mg and about 200 mg per litre of vitamin C, between about 20 and 60 mg per litre of vitamin B6, and between about 14% and about 18% glucose (w/w).
- the pH of the composition in solution may be about 3.4 to about 3.8.
- the composition may be in the form of a powder or granules, or may be in the form of an aqueous solution.
- the beverage composition of the invention comprises about 22 meq. per litre of sodium ions, about 17 meq. per litre of potassium ions, about 17 meq. per litre of magnesium ions, about 15 meq..per litre of phosphate ions, about 1 meq. per litre of citrate ions, about 160 mg per litre of vitamin C, about 40 mg per litre of vitamin B6, and about 16% glucose (w/w).
- the pH of the composition in solution may be about 3.4 to about 3.8.
- the composition may be in the form of a powder or granules, or may be in the form of an aqueous solution.
- the beverage composition of the invention is prepared by adding: sodium phosphate monobasic (400 to 550 mg), sodium chloride (60 to 80 mg), sodium citrate dihydrate (100 to 140 mg), potassium chloride (270 to 350 mg), magnesium sulfate (230 to 290 mg), vitamin C (30 to 50 mg), vitamin B6 (5 to 15 mg) and glucose (about 35 to 45 grams), to 250 mL of water, or other suitable liquid.
- the pH of the composition in solution may be about 3.4 to about 3.8.
- the composition may be in the form of a powder or granules, or may be in the form of an aqueous solution.
- the beverage composition of the invention is prepared by adding: sodium phosphate monobasic (470.0 mg), sodium chloride (69.0 mg), sodium citrate dihydrate (120.0 mg), potassium chloride (318.0 mg), magnesium sulfate (260.0 mg), vitamin C (40.0 mg), vitamin B6 (10.0 mg) and glucose (about 40 grams), to 250 mL of water, or other suitable liquid.
- the pH of the composition in solution may be about 3.4 to about 3.8.
- the composition may be in the form of a powder or granules, or may be in the form of an aqueous solution.
- the present invention provides an aqueous beverage composition
- glucose (30 to 50 grams), sodium ions (100 mg to 150 mg), potassium ions (120 mg to 180 mg), magnesium ions (20 mg to 55 mg), phosphate ions
- the beverage composition may also comprise additional components commonly used in beverages intended for use as body fluid supplements, such as but not limited to colouring agents, flavouring agents and preservatives.
- vitamins and minerals may also be added to the beverage composition, if desired.
- Suitable vitamins include, but are not limited to, vitamin Bl, vitamin B2, vitamin
- Suitable minerals include, but are not limited to selenium, chromium, calcium, iron, zinc, manganese and copper.
- the beverage composition may include protein.
- the beverage composition of the present invention may be used in the following situations:
- the present invention relates to a method of reducing one or more symptoms of altitude sickness in a subject comprising administration to said subject of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects.
- Altitude sickness is a pathological condition resulting from exposure to high altitudes. Altitude sickness typically occurs at heights above 2000 metres above sea level.
- Symptoms of altitude sickness include, but are not limited to: appetite loss, persistent rapid pulse, headache, nausea, fatigue, dizziness, weakness, insomnia, shortness of breath on exertion, peripheral edema, swollen hands and/or feet and/or face, and general malaise. Consumption of the composition of the first or fourth aspects effectively reduces one or more of the above symptoms of altitude sickness, even at altitudes above 6500 metres, hi one embodiment, the composition of the first; second, fourth or fifth to fourteenth aspects may be consumed in an amount of about 1 litre per day in order to reduce one or more symptoms of altitude sickness.
- the amount of the composition required may vary depending on the altitude and location, the subject's age, sex, weight and prevailing health and fitness at the particular time.
- the present invention relates to a method of reducing or preventing one or more symptoms of dehydration in a subject, comprising administration of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects.
- Typical symptoms associated with dehydration include, but are not limited to: headache, decreased blood pressure, thirst, appetite loss, constipation, darkened urine, dizziness and dry mouth.
- Consumption of the composition of the first, second, fourth or fifth to fourteenth aspects effectively reduces one or more symptoms of dehydration by replacing lost fluid and re-establishing electrolyte balance.
- the composition of the first or fourth aspects may be consumed before and during exercise, exertion or any other activity which leads to a depletion in the amount of fluid and electrolytes in the body.
- the composition may also be consumed by a subject already suffering from one or more symptoms of dehydration, thereby leading to a reduction in one or more of the symptoms thereof.
- the composition of the first, second, fourth or fifth to fourteenth aspects may be consumed: (i) 250 niL to 350 mL prior to exercise; (ii) 50 mL to 100 mL every 30 minutes during exercise; (iii) 250 mL to 300 mL post exercise.
- the above amounts will vary where more or less strenuous exercise is performed over a given period of time. In such a case, those skilled in the art will realise that greater or reduced amounts of the composition may be consumed at different time intervals depending on the subject's age, sex, weight and general health and fitness. A number of illnesses such as fever, severe diarrhea, vomiting and gastrointestinal disorders may lead to mild to severe dehydration.
- the beverage composition of the first or fourth aspect may be consumed by a subject suffering from an illness that results in dehydration in order to re-establish electrolyte balance and replace lost fluid.
- the present inventor has also discovered that the beverage composition of the first, second or fourth aspect is useful in reducing the blood alcohol concentration in a subject.
- the present invention relates to a method of reducing the blood alcohol concentration in a subject comprising administration of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects.
- the method involves the consumption by a subject of an amount of the composition of the first, second, fourth or fifth to fourteenth aspects, prior to consuming a first alcoholic drink, wherein the alcoholic drink comprises between approximately 1 and 3 standard drinks.
- the alcoholic drink comprises between approximately 1 and 3 standard drinks.
- between approximately 150 mL and 600 mL, or between about 150 mL and 550 mL, or between about 150 mL and 500 mL, or between about 15OmL and about 450 mL, or between about 150 mL and about 400 mL, or between about 150 mL and about 350 mL, or between about 175 mL and about 350 mL, or between about 180 mL and about 300 mL, or between about 20OmL and about 300 mL, or between about 225 mL and about 275 mL, or between about 240 mL and about 260 mL, or between about 250 mL and about 300 mL of the composition may be consumed between about 15 minutes and 1
- the method may comprise consumption of between approximately 150 mL and 600 mL, or between about 150 mL and 550 mL, or between about 150 mL and 500 mL, or between about 15OmL and about 450 mL, or between about 150 mL and about 400 mL, or between about 150 mL and about 350 mL, or between about 175 mL and about 350 mL, or between about 180 mL and about 300 mL, or between about 20OmL and about 300 mL, or between about 225 mL and about 275 mL, or between about 240 mL and about 260 mL, of the composition. Consumption of the composition in this manner in the above amounts may be continued after consumption of each subsequent alcoholic drink, or alternatively after every second or third subsequent alcoholic drink.
- 250 mL of the composition may be consumed 30 minutes prior to consuming a first alcoholic drink (which comprises between approximately 1 and 3 standard drinks), followed by a further 250 mL of the composition after consuming the first alcoholic drink, and prior to consuming a second alcoholic drink. Consumption of the composition in this way leads to a reduction in the blood alcohol concentration of the subject as compared to drinking the same amount of water prior to, and after, the first alcoholic drink.
- 250 mL to 300 mL of the composition may be consumed before drinking an alcoholic beverage, followed by a further 250 mL after consumption of a final alcoholic beverage.
- the present invention also relates to a method for supplementing the meals or replacing the meals of a subject undergoing medical treatment comprising administration to said subject of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects.
- the present invention further' relates to a method for enhancing the response of a subject to cancer therapy, said method comprising administration to said subject of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects.
- the present invention still further relates to the use of the composition of the first, second, fourth or fifth to fourteenth aspects as an adjunct to cancer therapy.
- compositions of the first, second, fourth or fifth to fourteenth aspects may be used as an effective meal supplement in persons undergoing cancer therapy as the compositions do not cause vomiting.
- the compositions may also be used to replace meals where the subject is able to only consume minimal (if any) food.
- compositions as a meal supplement or meal replacement is not limited to subjects undergoing cancer therapy but may be used in a subject undergoing any type of medical therapy or intervention wherein the subject is unable to consume an adequate amount of food or no food at all.
- compositions of the first, second, fourth or fifth to fourteenth aspects may be used to enhance the body's response to cancer therapy by limiting suppression of the immune system that occurs as a result of a lack of nutrition or nutritional imbalance. This method may be of particular relevance where the subject is undergoing' a biological therapy wherein the goal is to stimulate the immune system to fight cancer.
- compositions of the first, second, fourth or fifth to fourteenth aspects may form an integral part of cancer treatment methods when used in conjunction with known therapies, for example immunotherapy, chemotherapy and radiotherapy.
- the compositions of the invention have been found to be particularly effective when administered to subjects undergoing therapy for cancers of the head and neck, throat cancer and esophageal cancer who experience trouble swallowing and/or taking solid food.
- the amount of the composition that may be given to the subject may be between about 500 mL and about 1.5 litres per day, or as required. In one embodiment, the amount of the composition given to a subject per day is about 1 litre. Additional vitamins and/or minerals may also be added to the compositions where appropriate.
- the present invention provides a method for reducing or preventing cramps, said method comprising administration of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects.
- the cramp is a leg cramp.
- a subject in order to treat or prevent cramps, may consume about 250 mL to 300 mL of the composition, or alternatively about 40 g to 50 g of the composition in a concentrate form (e.g. as a powder in accordance with the second aspect).
- Example 1 Use of the composition of the invention in reducing blood alcohol concentration
- the test involved a total of 10 subjects ' (a mixture of males and females) having an average age of 22 years, an average weight of 87 kg and an average height of 1.86 metres. The subjects took no anti-hangover medication during the test and were all healthy, having no history of serious illness.
- the test method was as follows:
- each test individual was given an equal amount of food containing a minimal amount of fat prior to consuming an alcoholic beverage.
- composition X a composition comprising the following components in the amounts indicated per 25OmL of composition: (i) glucose 40 g;
- composition X A second 250 mL of composition X was given to each individual after consumption of the first 100 mL of liquor.
- Heart rate in a period of 30 seconds was measured every 10 minutes after the first 100 mL of liquor was consumed.
- a breath test for alcohol content was performed 10, 30, 50, 70 and 90 minutes after the first 100 mL of liquor was consumed.
- Example 2 Use of the composition of the invention as a food supplement
- a subject suffering from nasopharyngeal carcinoma was undergoing an intensive course of medical treatment that combined both chemotherapy and radiotherapy at the Queen Mary Hospital of Hong Kong.
- the subject suffered severe throat pain which made eating and drinking extremely difficult and painful. Hot drinks in particular caused severe throat pain.
- the chemotherapy also affected the subject's appetite . and caused a considerable amount of vomiting.
- composition of the second aspect in water as a meal supplement.
- the components included in the composition, and their amounts per 250 mL of the composition were as follows: (i) glucose 40 g; (ii) sodium ions 125 mg; . •
- citrate ions 450 mg The subject was able to consume the above composition without vomiting, and the composition was successfully used throughout the subject's remaining treatment as the sole meal supplement. As a result, the subject experienced a significant decrease in the number of vomiting episodes, and benefited from the electrolytes, vitamins and carbohydrate
- Example 3 Use of the composition of the invention in the treatment of symptoms associated with altitude sickness
- composition of the second aspect in water was consumed by a small group ofo professional mountaineers at 6500 metres whilst ascending Mt. Everest. The mountaineers found that following consumption of the composition, the symptoms associated with high altitude sickness were reduced.
- the components included in the composition, and their amounts per 250 mL of the composition were as follows:
- the inventor has also found that consumption of the composition of the second5 aspect whilst travelling on the Xining to Lhasa railway, the majority of which is 3200 metres above sea level, resulted in no observed symptoms of altitude sickness.
- the components included in the composition, and their amounts per 250 mL of the composition were as follows:
Abstract
The present invention relates to beverage compositions comprising the following components: sodium ions, potassium ions, magnesium ions, phosphate ions, citrate ions, vitamin B6 and carbohydrate, and also to uses thereof in subjects undergoing medical treatment.
Description
Body Fluid Supplement Compositions and Their Use in Subjects
Undergoing Medical Treatment
Technical Field The present invention relates to a body fluid supplement composition and uses thereof.
Background of the Invention
In order to maintain its physical capabilities, the human body requires optimal amounts of water, electrolytes, carbohydrate and a range of other minerals/nutrients, Where these optimal amounts are disturbed, physical and mental capabilities may be compromised.
The present inventor has developed a body fluid supplement composition which, surprisingly, finds utility in treating a number of ailments and conditions.
Summary of the Invention In a first aspect, the present invention provides an aqueous beverage composition comprising the following components: (i) sodium ions; (ii) potassium ions; (iii) magnesium ions; (iv) phosphate ions;
(v) citrate ions; (vi) vitamin B6; and (vii) carbohydrate.
The composition may consist essentially of the above components. The sodium ions may be present in an amount between about 10 meq. and about 35 meq. per litre of the beverage composition.
The potassium ions may be present in an amount between about 5 meq. and about 30 meq. per litre of the beverage composition.
The magnesium ions may be present in an amount between about 5 meq. and about 25 meq. per litre of the beverage composition.
The phosphate ions may be present in an amount between about 1 meq. and about 55 meq. per litre of the beverage composition. , •
The citrate ions may be present in an amount between about 0.1 meq. and about 45 meq. per litre of the beverage composition. The vitamin B6 may be present in an amount between about 0.1 mg and about 200 mg per litre of the beverage composition.
The carbohydrate may be present in an amount between about 2% and about 20% by weight of the total beverage composition (w/w).
The carbohydrate may be a monosaccharide or a disaccharide, or a mixture thereof. In one embodiment, the carbohydrate is a monosaccharide, for example glucose, fructose, mannose or galactose, or a mixture thereof.
The sodium ions may be present by inclusion of sodium phosphate, sodium chloride, sodium citrate, sodium sulfate or any combination thereof in the beverage composition.
The potassium ions may be present by inclusion of potassium chloride, potassium citrate, potassium phosphate, potassium sulfate or any combination thereof in the beverage composition.
The magnesium ions may be present by inclusion of magnesium sulfate, magnesium phosphate, magnesium citrate, magnesium • chloride or any combination thereof in the beverage composition. The phosphate ions may be present by inclusion of sodium phosphate, potassium phosphate, magnesium phosphate or any combination thereof in the beverage composition.
The citrate ions may be present by inclusion of sodium citrate, potassium citrate, magnesium citrate or any combination thereof in the beverage composition.
The composition may further comprise vitamin C. The vitamin C may be present in an amount between about 30 mg and about 2000 mg per litre of the beverage composition.
In one embodiment, the beverage composition may be isotonic.
In another embodiment, the beverage composition may have a pH in the range of about 3.0 to about 5.0, or from about 3.0 to about 4.5, or from about 3.0 to about 4.0, or from about 3.2 to about 4.0, or from about 3.2 to about 3.8, or from about 3.4 to about 3.8.
The composition may be dried to form, for example, a powder, granules or tablets.
In a second aspect, the present invention provides a concentrate for use in preparing an aqueous beverage composition, the concentrate comprising a mixture of components in amounts such that when constituted with water or an appropriate liquid to form the aqueous beverage composition, the following proportions of the components are obtained: (i) sodium ions in an amount between about 10 meq. and about 35 meq. per litre of the beverage composition.
(ii) potassium ions in an amount between about 5 meq and about 30 meq. per litre of the beverage composition.
(iii) magnesium ions in an amount between about 5 meq. and about 25 meq. per litre of the beverage composition.
(iv) phosphate ions in an amount between about 1 meq. and about 55 meq. per litre of the beverage composition.
(v) citrate ions in an amount between about 0.1 meq. and about 45 meq. per litre of the beverage composition. (vi) vitamin B6 in an amount between about 0.1 mg and 200 mg per litre of the beverage composition; and
(viii) carbohydrate in an amount between about 2% and about 20% by weight of the total beverage composition.
The concentrate may be in the form of a powder, granules or tablets. In a third aspect, the present invention provides a process for the manufacture of an aqueous beverage composition, wherein the concentrate of the second aspect is mixed with a quantity of water, or an appropriate liquid, sufficient to provide a solution suitable for consumption by drinking.
In a fourth aspect, the present invention provides an aqueous beverage composition whenever prepared by the process of the third aspect.
In a fifth aspect, the beverage composition of the invention comprises between about 12 meq. and about 32 meq. per litre of sodium ions, between about 10 meq. and about 25 meq. per litre of potassium ions, between about 7 meq. and about 20 meq. per litre of magnesium ions, between about 5 meq. and 25 meq. per litre of phosphate ions, between 1 and 15 meq. per litre of citrate ions; between 20 mg and 40 mg per litre of vitamin B6 and between 10% and 20% glucose (w/w). This composition may additionally comprise
vitamin C in an amount between • about 250 mg and about 1200 mg per litre. The composition may have a pH of about 3.4 to 3.8.
In a sixth aspect, the beverage composition of the invention comprises about 22 meq. per litre of sodium ions, about 17 meq. per litre of potassium ions, about 13 meq. per litre of magnesium ions, about 10 meq. per litre of phosphate ions, about 5 meq. per litre of citrate ions, about 20 mg per litre, of vitamin B6 and about 16% glucose (w/w). The composition may have a pH of about 3.4 to 3.8.
In a seventh aspect, the beverage composition of the invention comprises about 22 meq. per litre of sodium ions, about 17 meq. per litre of potassium ions, about 13 meq. per litre of magnesium ions, about 10 meq. per litre of phosphate ions, about 5 meq. per litre of citrate ions, 20 mg per litre of vitamin B6, 16% glucose (w/w), and 480 mg per litre of vitamin C. The composition may have a pH of about 3.4 to 3.8.
In an eighth aspect, the beverage composition of the invention comprises about 22 meq. per litre of sodium ions, about 17 meq. per litre of potassium ions, about 13 meq. per litre of magnesium ions, about 10 meq. per litre of phosphate ions, about 5 meq. per litre of citrate ions, about 40 mg per litre of vitamin B6, about 16% glucose (w/w), and 1000 mg per litre of vitamin C. The composition may have a pH of about 3.4 to 3.8.
In a ninth aspect, the beverage composition of the invention comprises about 22 meq. per litre of sodium ions, about 17 meq. per litre of potassium ions, about 13 meq. per litre of magnesium ions, about 10 meq. per litre of phosphate ions, about 5 meq. per litre of citrate ions, about 40 mg per litre of vitamin B6, about 16% glucose (w/w), and about 480 mg per litre of vitamin C. The composition may have a pH of about 3.4 to 3.8.
In a tenth aspect, the beverage composition of the invention comprises between about
12 meq. and about 32 meq. per litre of sodium ions, between about 10 meq. and about 25 meq. per litre of potassium ions, between about 12 meq. and about 22 meq. per litre of magnesium ions, between about 10 meq. and about 20 meq. per litre of phosphate ions, between 0.1 meq. and about 8 meq. per litre of citrate ions, between about 50 mg and about
200 mg per litre of vitamin C, between about 10 and 80 mg per litre of vitamin B6, and between about 10% and about 20% glucose (w/w). The pH of this composition may be about 3.4 to about 3.8.
In an eleventh aspect, the beverage composition of the invention comprises between
about 17 meq. and about 27 meq. per litre of sodium ions, between about 13 meq. and about 21 meq. per litre of potassium ions, between about 13 meq. and about 21 meq. per litre of magnesium ions, between about 11 meq. and about 17 meq. per litre of phosphate ions, between about 0.25 meq. and about 5 meq. per litre of citrate ions, between about 100 mg and about 200 mg per litre of vitamin C, between about 20 and 60 mg per litre of vitamin B6, and between about 14% and about 18% glucose (w/w). The pH of this composition maybe about 3.4 to about 3.8.
In a twelfth aspect, the beverage composition of the invention comprises about 22 meq. per litre of sodium ions, about 17 meq. per litre of potassium ions, about 17 meq. per litre of magnesium ions, about 15 meq. per litre of phosphate ions, about 1 meq. per litre of citrate ions, about 160 mg per litre of vitamin C, about 40 mg per litre of vitamin B6, and about 16% glucose (w/w). The pH of this composition may be about 3.4 to about 3.8.
In a thirteenth aspect, the beverage composition of the invention is prepared by adding: sodium phosphate monobasic (400 to 550 mg), sodium chloride (60 to 80 mg), sodium citrate dihydrate (100 to 140 mg), potassium chloride (270 to 350 mg), magnesium sulfate (230 to 290 mg), vitamin C (30 to 50 mg), vitamin B6 (5 to 15 mg) and glucose (about 35 to 45 grams), to 250 mL of water, or other suitable liquid. The pH of this composition may be about 3.4 to about 3.8.
In a fourteenth aspect, the beverage composition of the invention is prepared by adding: sodium phosphate monobasic (470.0 mg), sodium chloride (69.0 mg), sodium citrate dihydrate (120.0 mg), potassium chloride (318.0 mg), magnesium sulfate (260.0 mg), vitamin C (40.0 mg), vitamin B6 (10.0 mg) and glucose (about 40 grams), to 250 mL of water, or other suitable liquid. The pH of this composition may be about 3.4 to about 3.8. In a fifteenth aspect, the present invention provides a method of reducing or preventing one or more symptoms of altitude sickness in a subject, said method comprising administration to said subject of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects.
The amount of vitamin B6 present in- the composition used in the fifteenth aspect may be between about 10 mg and about 50 mg per litre of the beverage composition.
In a sixteenth aspect, the present invention provides a method of reducing or
preventing one or more symptoms of dehydration in a subject, said method comprising administration to said subject of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects. . '
The amount of vitamin B6 present in the composition used in the sixteenth aspect may be between about 2 mg and about 10 mg per litre of the beverage composition. In one embodiment, the amount of vitamin B6 present in the composition used in the sixteenth aspect may be about 5 mg per litre of the beverage composition.
In a seventeenth aspect, the present invention provides a method of reducing the blood alcohol concentration in a subject, said method comprising administration to said subject of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects.
The method may comprise the step of administering the composition to the subject before the subject drinks a first alcoholic drink.
The method may further comprise the step of administering the composition to the subject after the subject drinks a first alcoholic drink, and prior to the subject drinking a second alcoholic drink.
The method may further comprise the step of administering the composition to the subject after each subsequent alcoholic drink consumed after the first alcoholic drink.
The amount of vitamin B6 present in the composition used in the seventeenth aspect may be between about 10 mg and about 25 mg per litre of the beverage composition.
In an eighteenth aspect, the present invention provides a method for supplementing the meals or replacing the meals of a subject undergoing medical treatment, said method comprising administration to said subject of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects. The medical treatment may be any type of medical treatment or intervention that causes a reduction in the appetite of the subject.
The medical treatment may be a surgical procedure such as an appendix operation, or a treatment in which anaesthetic or pain killers are used, or alternatively a treatment that results in diarrhea in the subject, or a treatment that involves drugs that suppress appetite and/or cause nausea.
The medical treatment may be cancer therapy.
The cancer therapy may be surgery, chemotherapy, radiotherapy, hormone therapy or immunotherapy.
The subject may be a human.
In a nineteenth aspect, the present invention provides a method for enhancing the response of a subject to cancer therapy, said method comprising administration to said subject of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects. m a twentieth aspect, the present invention provides a method for the treatment of cancer in a subject in need of said treatment, said method comprising administering to said subject an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects, together with chemotherapy and/or radiotherapy and/or biological therapy.
In a twenty- first aspect, the present invention provides the use of the composition of the first, second, fourth or fifth to fourteenth aspects as an adjunct to cancer therapy. In a twenty-second aspect, the present invention provides a method for reducing or preventing cramps, said method comprising administration of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects.
In the methods of the invention, the composition may be given in the form of a beverage composition, or alternatively in the form of a concentrate as defined in the second aspect.
The compositions of the first or fifth to fourteenth aspects may be in the form of a concentrate that is used for preparing an aqueous beverage composition, the concentrate comprising a mixture of components in amounts such that when constituted with water or an appropriate liquid to form the aqueous beverage composition, the proportions of the components are those given in the first or fifth to fourteenth aspects.
Definitions
As used herein, the term "carbohydrate" refers to monosaccharides, oligosaccharides, complex polysaccharides, or mixtures thereof.
As used herein, the term "comprising" means "including principally, but not necessarily solely". Furthermore, variations of the word "comprising", such as "comprise" and "comprises", have correspondingly varied meanings.
As used herein, the term "effective amount", includes within its meaning an amount of the composition that provides the desired effect. The exact amount required will vary from subject to subject depending on factors such as the subject's general health, age and the condition for which they are receiving treatment. As used herein, the term "standard drink(s)" refers to a drink that contains about 10 grams of alcohol.
As used herein, the terms "reduction" and "reducing" in the context of "one or more symptoms" encompass the elimination or substantial elimination of a symptom, the arresting of a symptom such that the symptom does not worsen, and the amelioration, including partial amelioration, of a symptom. By these terms, it will also be understood that where a condition to which the present invention relates may display more than one symptom, the elimination, substantial elimination, arresting or amelioration need not be of all symptoms of the condition, but maybe of one or more symptoms thereof.
Brief Description of the Drawings Figure 1 shows the blood alcohol concentrations (mg/L) after a given time in individuals consuming a combination of (i) alcohol and a composition in accordance with the invention (composition X, — ♦— ■ ), and (ii) alcohol and water ( -*— ).
Figure 2 shows a heart rate measurement performed every 10 minutes in individuals consuming a combination of (i) alcohol and a composition in accordance with the invention (composition X, ♦ ), and (ii) alcohol and water (—«—).
Detailed Description of the Invention
In one aspect, the present invention relates to an aqueous beverage composition comprising sodium ions, potassium ions, magnesium ions, phosphate ions, citrate ions, vitamin B6 and carbohydrate. The present invention also relates to a concentrate for use in preparing an aqueous beverage composition, the concentrate comprising a mixture of components in amounts such that when constituted with water, or an appropriate liquid, to form the aqueous beverage composition, specific proportions of the components are obtained. The present invention also relates to a process for the manufacture of an aqueous beverage composition, wherein a concentrate is mixed with a quantity of water, or an
appropriate liquid, sufficient to provide a solution suitable for consumption by drinking, and a beverage composition obtained by such a process.
The amount of sodium ions present in the aqueous beverage composition may be between about 10 meq. and about 35 meq. per litre of the beverage composition, or between about 12 meq. and about 35 meq., or between about 14 meq. and about 35 meq., or between about 16 meq. and about 35 meq., or between about 18 meq. and about 35 meq., or between about 20 meq. and about 35 meq., or between about 22 meq. and about 35 meq., or between about 24 meq. and about 35 meq., or between about 26 meq. and about 35 meq., or between about 28 meq. and about 35 meq., or between about 10 meq. and about 32 meq., or between about 10 meq. and about 30 meq., or between about 10 meq., and about 28 meq., or between about 10 meq. and about 26 meq., or between about 10 meq. and about 24 meq., or between about 10 meq. and about 22 meq., or between about 10 meq. and about 20 meq,, or between about 10 meq. and about 18 meq., or between about 10 meq. and about 16 meq., or between about 12 meq. and about 35 meq., or between about 14 meq. and about 32 meq., or between about 16 meq. and about 30 meq., or between about 17 meq. and about 28 meq., or between about 18 meq. and about 26 meq., or between about 20 meq. and about 24 meq. per litre of the beverage composition.
In one embodiment, the amount of sodium ions present in the beverage composition may be 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 meq. per litre of the beverage composition.
The amount of potassium ions present in the aqueous beverage composition may be between about 5 meq. and about 30 meq. per litre of the beverage composition, or between about 7 meq. and about 30 meq., or between about 9 meq. and about 30 meq., or between about 11 meq. and about 30 meq., or between about 13 meq. and about 30 meq., or between about 15 meq. and about 30 meq., or between about 17 meq. and about 30 meq., or between about 19 meq. and about 30 meq., or between about 21 meq. and about 30 meq., or between about 23 meq. and about 30 meq., or between about 25 meq. and about 30 meq., or between about 5 meq. and about 28 meq., or between about 5 meq. and about 26 meq., or between about 5 meq. and about 24 meq., or between about 5 meq. and about 22 meq., or between about 5 meq. and about 20 meq., or between about 5 meq. and about
18 meq., or between about 5 meq. and about 16 meq., or between about 5 meq. and about 14 meq., or between about 5 meq. and about 12 meq., or between about 5 meq. and about 10 meq., or between 10 meq. and about 25 meq., or between about 12 meq. and about 23 meq., or between about 14 meq. and about 21 meq., or between about 15 meq. and about 19 meq. per litre of the beverage composition.
In one embodiment, the amount of potassium ions present in the beverage composition may be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 meq. per litre of the beverage composition.
The amount of magnesium ions present in the composition may be between about 5 meq. and about 25 meq. per litre of the beverage composition, or between about 5 meq. and about 23 meq., or between about 5 meq. and about 21 meq., or between about 5 meq. and about 21 meq., or between about 5 meq. and about 19 meq., or between about 5 meq. and about 17 meq., or between about 5 meq. and about 16 meq., or between about 5 meq. and about 15 meq., or between about 5 meq: and about 14 meq., or between about 6 meq. and about 25 meq, or between about 7 meq. and about 25 meq, or between about 9 meq. and about 25 meq., or between about 11 meq. and about 25 meq., or between about 12 meq. and about 25 meq., or between about 14 meq. and about 25 meq., or between about 16 meq. and about 25 meq., or between about 18 meq. and about 25 meq., or between about 20 meq. and 25 meq., or between about 22 meq. and about 25 meq., or between about 6 meq. and about 22 meq., or between about 7 meq. and about 20 meq., or between about 8 meq. and about 20 meq., or between about 10 meq. and about 18 meq., or between about 11 meq. and 16 meq., or between about 11 meq. and about 15 meq., or between about 11 meq. and about 14 meq., or between about 12 meq. and about 23 meq., or between about 13 meq. and about 20 meq., or between about 13 meq. and about 17 meq. per litre of the beverage composition.
In one embodiment, the amount of magnesium ions present in the beverage composition may be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 meq. per litre of the beverage composition.
The phosphate ions in the beverage composition are present as mixtures of PO4 3", H2PO4 " and HPO4 2", the relative concentrations of which are pH dependent. As such, the term "phosphate" is understood to encompass PO4 3", H2PO4 " and HPO4 2", unless otherwise
specifically stated. At a pH of about 3.4 to 3.8, H2PO4 " is by far the most abundant species in solution, whereas at pH 7.4, HPO4 2" is the most abundant species.
The amount of phosphate ioris present in the composition may be between about 1 meq. and about 55 meq., or between about 2 meq. and about 55 meq., or between about 4 meq. and about 55 meq., or between about 6 meq. and about 55 meq., or between about 8 meq. and about 55 meq., or between about 10 meq. and about 55 meq., or between about 12 meq. and about 55 meq., or between about 14 meq. and about 55 meq., or between about 16 meq. and about 55 meqk, or between about 18 meq. and about 55 meq., or between about 20 meq. and about 55 meq., or between about 22 meq. and about 55 meq., or between about 24 meq. and about 55 meq., or between about 26 meq. and about 55 meq., or between about 28 meq. and about 55 meq., or between about 30 meq. and about 55 meq., or between about 32 meq. and about 55 meq., or between about 34 meq. and about 55 meq., or between about 36 meq. and about 55 meq., or between about 38 meq. and about 55 meq., or between about 40 meq. and about 55 meq., or between about 42 meq. and about 53 meq., or between about 8 meq. and about 50 meq., or between about 8 meq. and about 47 meq., or between about 8 meq. and about 43 meq., or between about 8 meq. and about 41 meq., or between about 8 meq. and about 39 meq., or between about 8 meq. and about 37 meq., or between about 8 meq. and about 35 meq., or between about 8 meq. and about 33 meq., or between about 8 meq. and about 31 meq., or between about 8 meq. and about 29 meq., or between about 8 meq. and about 27 meq., or between about 8 meq. and about 25 meq., or between about 8 meq. and about 23 meq., or between about 8 meq. and about 21 meq., or between about 8 meq. and about 19 meq., or between about 8 meq. and about 17 meq., or between about 8 meq. and about 15 meq., or between 15 meq. and about 45 meq., or between about 18 meq. and about 42 meq., or between about 20 meq. and about 40 meq., or between about 22 meq. and about 38 meq., or between about 24 meq. and about 36 meq., or between about 26 meq. and about 34 meq., or between about 28 meq. and about 32 meq:, or between about 35 meq. and about 50 meq., or between about 40 meq. and about 50 meq., or between about 25 meq. and 55 meq, or between about 28 meq. and about 50 meq., or between about 1 meq. and about 30 meq., or between about 3 meq. and about 28 meq., or between about 5 meq. and about 25 meq., or between about 6 meq. and about 22 meq., or between about or between about 8 meq. and
about 21 meq., or between about 9 meq. and about 20 meq., or between about 10 meq. and about 20 meq, or between about 12 meq., and about 18 meq., or about 10 meq., or about 15 meq. per litre of the beverage composition.
In one embodiment, the amount of phosphate ions present in the beverage
5 composition may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54 or 55 meq. per litre of the beverage composition.
When adjusted to a pH of about 3.6, the amount of phosphate ions in the beverage composition (as H2PO4 ") may be between about 1 meq. and about 30 meq., or betweeno about 3 meq. and about 28 meq., or between about 5 meq. and about 25 meq., or between about 6 meq. and about 22 meq., or between about or between about 8 meq. and about 21 meq., or between about 9 meq. and about 20'meq., or between about 10 meq. and about 20 meq, or between about 12 meq., and about 18 meq., or about 10 meq., or about 15 meq. per litre of the beverage composition. s The amount of phosphate ions present in the beverage composition (as either PO4 3",
H2PO4 ", HPO4 2") may be between about 0.25 and about 3.5, or between about 0.5 and about 3.25, or between about 0.5 and about 3, or between about 0.5 and about 2.5, or between about 0.5 and about 2.25, or between about 0.5 and about 2, or between about 0.75 and about 1.75, or about 1.5, or about 1, grams per litre of the beverage composition. 0 The citrate ions in the beverage composition are present as mixtures of C6H7O7 ",
C6H6O7 " and C6H5O7 ", the relative concentrations of which are pH dependent. As such, the term "citrate" is understood to encompass C6H7O7 ", C6H6O7 2" and C6HsO7 3", unless otherwise specifically stated. At a pH of about 3.4 to 3.8, C6H7O7 " is the most abundant species. 5 The amount of citrate ions present in the composition may be between about 0.1 meq. and about 45 meq., or between about 0.5 meq. and about 45 meq., or between about 1 meq. and about 45 meq., or between about 2 meq. and about 45 meq., or between about 4 meq. and about 45 meq., or between about 6 meq. and about 45 meq., or between about 8 meq. and about 45 meq., or between about 10 meq. and about 45 meq., or between abouto 12 meq. and about 45 meq., or between about 14 meq. and about 45 meq., or between about 16 meq. and about 45 meq., or between about 18 meq. and about 45 meq., or
between about 20 meq. and about 45 nieq., or between about 22 meq. and about 45 meq., or between about 24 meq. and about 45 meq., or between about 26 meq. and about 45 meq., or between about 28 meq. and about 45 meq., or between about 30 meq. and about 45 meq., or between about 32 meq. and about 45 meq., or between about 34 meq. and about 45 meq., or between about 36 meq. and about 45 meq., or between about 38 meq. and about 45 meq., or between about 40 meq. and about 45 meq., or between about 10 meq. and about 43 meq., or between about 10 meq. and about 41 meq., or between about 10 meq. and about 39 meq., or between about 10 meq. and about 37 meq., or between about 10 meq. and about 35 meq., or between about 10 meq. and about 33 meq., or between about 10 meq. and about 31 meq., or between about 10 meq. and about 29 meq., or between about 10 meq. and about 27 meq., or between about 10 meq. and about 25 meq., or between about 10 meq. and about 23 meq., or between about 10 meq. and about 21 meq., or between about 10 meq. and about 19 meq., or between about 10 meq. and about 17 meq., or between about 10 meq. and about 15 meq., or between 15 meq. and about 45 meq., or between about 18 meq. and about 42 meq., or between about 20 meq. and about 40 meq., or between about 22 meq. and about 38 meq., or between about 22 meq. and about 36 meq., or between about 24 meq. and about 34 meq., or between about 26 meq. and about 32 meq., or between about 26 meq. and about 30 meq., or between about 1 meq. and about 30 meq., or. between about 1 meq. and about 25 meq., or between about 1 meq. and about 20 meq., or between about 1 meq. and about 15 meq., or between about 1 meq. and about 12 meq., or between about 1 meq. and about 10 meq., or between about 0.25 meq. and about 15 meq., or between about 0.5 meq. and about 15 meq., or between about 1 meq. and about 13 meq., or between about 1 meq. and about 12 meq., or between about 1 meq. and about 10 meq., or" between about 1 meq. and about 8 meq., or between about 1 meq. and about 7 meq., or between about 0.25 meq. and about 12 meq., or between about 0.25 meq. and about 10 meq., or between about 0.25 meq, and about 8 meq., or about 5 meq., or about 1 meq. per litre of the beverage composition.
In one embodiment, the amount of citrate ions present in the beverage composition may be 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,- 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, or 45 meq. per litre of the beverage composition.
When adjusted to a pH of about 3.6, the amount of citrate ions in the beverage composition (as C6H7O7 ") may be between about 0.25 meq. and about 15 meq., or between about 0.5 meq. and about 15 meq., or between about 1 meq. and about 13 meq., or between about 1 meq. and about 12 meq., or between about 1 meq. and about 10 meq., or between
5 about 1 meq. and about 8 meq., or between about 1 meq. and about 7 meq., or between about 0.25 meq. and about 12 meq., or between about 0.25 meq. and about 10 meq., or between about 0.25 meq. and about 8 meq., or about 5 meq., or about 1 meq. per litre of the beverage composition.
The amount of citrate ions present in the beverage composition (as either C6H7O7 ",o C6H6O7 2" and C6H5O7 3") may be between about 0.1 and about 3.5, or between about 0.1 and about 3.25, or between about 0.1 and about 3, or between about 0.1 and about 2.5, or between about 0.1 and about 2.25, or between about 0.1 and about 2, or between about 1 and about 2.5, or between about 1 and about 2.25, or between about 1.25 and about 2.25, or between about 1.5 and about 2, or between about 0.1 and about 1, or between about 0.15 and about 0.75, or between about. 0.1 and about 0.5, grams per litre of the beverage composition.
The amount of vitamin B6 present in the composition may be between about 0.1 mg and 200 mg per litre of the beverage composition, or between about 0.1 mg and 180 mg, or between about 0.1 mg and about 170 mg, or between about 0.1 mg and about 160 mg, oro between about 0.1 mg and about 150 mg, or between about 0.1 mg and about 140 mg, or between about 0.1 mg and about 130 mg, or between about 0.1 mg and about 120 mg, or between about 0.1 mg and about 110 mg, or between about 0.1 mg and about 100 mg, or between about 0.1 mg and about 90 mg, or between about 0.1 mg and about 80 mg, or between about 0.1 mg and about 70 mg, or between about 0.1 mg and about 60 mg, or5 between about 0.1 mg and about 50 mg, or between about 0.1 and about 45 mg, or between about 1 and about 200 mg, or between about 5 mg and about 200 mg, or between about 10 mg and about 200 mg, or between about 20 mg and about 200 mg, or between about 30 mg and about 200 mg, or between about 40 mg and about 200 mg, or between about 50 mg and about 200 mg, or between about 60 mg and about 200 mg, or between about 70 mgo and about 200 mg, or between about 80 mg and about 200 mg, or between about 90 mg and about 200 mg, or between about 100 mg and about 200 mg, or between about 110 mg
and about 200 mg, or between about 5 mg and about 110 mg, or between about 5 mg and about 100 mg, or between about 10 mg and about 100 mg, or between about 10 mg and about 90 mg, or between about 10 mg and about 80 mg, or between about 10 mg and about 70 mg, or between about 10 mg and about 60 mg, or between about 10 mg and about 50 mg, or between about 15 mg and about 45 mg, or between about 20 mg and about 40 mg of vitamin B6 per litre of the beverage composition. In one embodiment, the amount of vitamin B6 per litre of the beverage composition may be 0.1, 0.5, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190 or 200 mg. The carbohydrate included in the beverage compositions may be present in an amount between about 2% and about 20% by weight of the beverage composition, or between about 2% and about 19%, or between about 2% and about 18%, or between about 2% and about 17%, or between about 2% and about 16%, or between about 2% and about 13%, or between about 2% and about 12%, or between about 2% and about 11%, or between about 2% and about 10%, or between about 7% and about 20%, or between about 9 % and about 20%, or between about 10% and about 20%, or between about 11% and about 20%, or between about 12% and about 20%, or between about 13% and about 20%, or between about 14% and about 20%, or between about 14% and about 18%, or between about 15% and about 18% or between about 15% and about 17%. In one embodiment, the carbohydrate is present in 16% by weight of the total beverage composition.
The meq. per litre ratio of sodium ions to potassium ions may be between about 1.0 and about 1.8, or between about 1.1 and about 1.75, or between about 1.1 and about 1.7, or between about 1.15 and about 1.6, or between about 1.2 and about 1.55, or between about 1.2 and about 1.5, or between about 1.2 and about 1.45, or between about 1.2 and about 1.4, or between about 1.25 and about 1.35, or about 1.3.
The beverage composition of the first aspect may be prepared by simply adding the relevant components to an aqueous medium with or without agitation. The resultant solution may then be consumed by drinking. The beverage composition of the first aspect may be dehydrated to provide a dry mixture of the composition. This dry mixture, either as powder, granules or tablets, can be later re-dissolved in an appropriate amount of water, or other appropriate liquid, to re-establish the drinkable beverage composition.
The concentrate of the second aspect may be prepared by simply mixing the relevant components together in the necessary amounts. The concentrate may be prepared in the form of a powder, granules or tablets, which may be reconstituted for use by the addition of water, or any other appropriate liquid. The reconstitution is made with appropriate amounts of water/liquid to ensure that the beverage obtained comprises the components in the proportions given in the second aspect. In another embodiment, the composition may be solubilised in water/liquid and then frozen to provide "ice blocks".
The beverage composition of the invention provides an advantage over many other currently available body fluid supplement beverages in that it has improved palatability. The beverage composition has a taste that is similar to apple juice.
In one embodiment, the beverage composition of the invention comprises between about 10 meq. and about 32 meq. per litre -of sodium ions, between about 10 meq. and about 25 meq. per litre of potassium ions, between about 8 meq. and about 25 meq. per litre of magnesium ions, between about 10 meq. and about 50 meq. per litre of phosphate ions, between about 0.5 meq. and about 30 meq. per litre of citrate ions, between about 10 mg and about 60 mg per litre of vitamin B6 and between about 10% and 20% glucose (w/w). This composition may additionally ^comprise vitamin C in an amount between about 100 mg and about 1500 mg per litre. The composition may be in the form of a powder or granules, or may be in the form of an aqueous solution. In another embodiment, the beverage composition of the invention comprises between about 12 meq. and about 32 meq. per litre of sodium ions, between about 10 meq. and about 25 meq. per litre of potassium ions, between about 7 meq. and about 20 meq. per litre of magnesium ions, between about 5 meq. and about 25 meq. per litre of phosphate ions, between about 1 meq. and about 15 meq. per litre of citrate ions, between about 20 mg and about 40 mg per litre of vitamin B6 and between about 10% and 20% glucose (w/w). This composition may additionally comprise vitamin C in an amount between about 250 mg and about 1200 mg per litre. The composition in solution may have a pH of about 3.4 to 3.8. The composition may be in the form of a powder or granules, or may be in the form of an aqueous solution. hi another embodiment, the beverage composition of the invention comprises about
22 meq. per litre of sodium ions, about 17 meq. per litre of potassium ions, about 13 meq.
per litre of magnesium ions, about 10 meq. per litre of phosphate ions, about 5 meq. per litre of citrate ions, about 20 mg per litre of vitamin B6 and about 16% glucose (w/w). The composition in solution may have a pH of about 3.4 to 3.8. The composition may be in the form of a powder or granules, or may be in the form of an aqueous solution. In another embodiment, the beverage composition of the invention comprises about
22 meq. per litre of sodium ions, about 17 meq. per litre of potassium ions, about 13 meq. per litre of magnesium ions, about 10 meq. per litre of phosphate ions, about 5 meq. per litre of citrate ions, 20 mg per litre of vitamin B6, 16% glucose (w/w), and 480 mg per litre of vitamin C. The composition in solution may have a pH of about 3.4 to 3.8. The composition may be in the form of a powder or granules, or may be in the form of an aqueous solution. hi another embodiment, the beverage composition of the invention comprises about 22 meq. per litre of sodium ions, about 17 meq. per litre of potassium ions, about 13 meq. per litre of magnesium ions, about 10 meq. per litre of phosphate ions, about 5 meq. per litre of citrate ions, about 40 mg per litre of vitamin B6, about 16% glucose (w/w), and 1000 mg per litre of vitamin C. The composition in solution may have a pH of about 3.4 to 3.8. The composition may be in the form of a powder or granules, or may be in the form of an aqueous solution.
In another embodiment, the beverage composition of the invention comprises about 22 meq. per litre of sodium ions, about 17 meq. per litre of potassium ions, about 13 meq. per litre of magnesium ions, about 10 meq. per litre of phosphate ions, about 5 meq. per litre of citrate ions, about 40 mg per litre of vitamin B6, about 16% glucose (w/w), and about 480 mg per litre of vitamin C. The composition in solution may have a pH of about 3.4 to 3.8. The composition may be in the form of a powder or granules, or may be in the form of an aqueous solution. hi a further embodiment, the beverage composition of the invention comprises between about 12 meq. and about 32 meq. per litre of sodium ions, between about 10 meq. and about 25 meq. per litre of potassium ions, between about 12 meq. and about 22 meq. per litre of magnesium ions, between about 10 meq. and about 20 meq. per litre of phosphate ions, between 0.1 meq. and about 8 meq. per litre of citrate ions, between about 50 mg and about 200 mg per litre of vitamin C, between about 10 and 80 mg per litre of
vitamin B6, and between about 10% and about 20% glucose (w/w). The pH of the composition in solution may be about 3.4 to about 3.8. The composition may be in the form of a powder or granules, or may be in the form of an aqueous solution. hi a further embodiment, the beverage composition of the invention comprises between about 17 meq. and about 27 meq. per litre of sodium ions, between about 13 meq. and about 21 meq. per litre of potassium ions, between about 13 meq. and about 21 meq. per litre of magnesium ions, between about 11 meq. and about 17 meq. per litre of phosphate ions, between about 0.25 meq. and about 5 meq. per litre of citrate ions between about 100 mg and about 200 mg per litre of vitamin C, between about 20 and 60 mg per litre of vitamin B6, and between about 14% and about 18% glucose (w/w). The pH of the composition in solution may be about 3.4 to about 3.8. The composition may be in the form of a powder or granules, or may be in the form of an aqueous solution. hi a further embodiment, the beverage composition of the invention comprises about 22 meq. per litre of sodium ions, about 17 meq. per litre of potassium ions, about 17 meq. per litre of magnesium ions, about 15 meq..per litre of phosphate ions, about 1 meq. per litre of citrate ions, about 160 mg per litre of vitamin C, about 40 mg per litre of vitamin B6, and about 16% glucose (w/w). The pH of the composition in solution may be about 3.4 to about 3.8. The composition may be in the form of a powder or granules, or may be in the form of an aqueous solution. In yet another embodiment, the beverage composition of the invention is prepared by adding: sodium phosphate monobasic (400 to 550 mg), sodium chloride (60 to 80 mg), sodium citrate dihydrate (100 to 140 mg), potassium chloride (270 to 350 mg), magnesium sulfate (230 to 290 mg), vitamin C (30 to 50 mg), vitamin B6 (5 to 15 mg) and glucose (about 35 to 45 grams), to 250 mL of water, or other suitable liquid. The pH of the composition in solution may be about 3.4 to about 3.8. The composition may be in the form of a powder or granules, or may be in the form of an aqueous solution. hi yet another embodiment, the beverage composition of the invention is prepared by adding: sodium phosphate monobasic (470.0 mg), sodium chloride (69.0 mg), sodium citrate dihydrate (120.0 mg), potassium chloride (318.0 mg), magnesium sulfate (260.0 mg), vitamin C (40.0 mg), vitamin B6 (10.0 mg) and glucose (about 40 grams), to 250 mL of water, or other suitable liquid. The pH of the composition in solution may be about 3.4
to about 3.8. The composition may be in the form of a powder or granules, or may be in the form of an aqueous solution.
In a further embodiment, the present invention provides an aqueous beverage composition comprising: glucose (30 to 50 grams), sodium ions (100 mg to 150 mg), potassium ions (120 mg to 180 mg), magnesium ions (20 mg to 55 mg), phosphate ions
(200 mg to 800 mg), vitamin C (80 mg to 1000 mg), vitamin B6 (1 mg to 20 mg) and citrate ions (200 mg to 900 mg), per 250 mL of composition.
The beverage composition may also comprise additional components commonly used in beverages intended for use as body fluid supplements, such as but not limited to colouring agents, flavouring agents and preservatives.
Additional vitamins and minerals may also be added to the beverage composition, if desired. Suitable vitamins include, but are not limited to, vitamin Bl, vitamin B2, vitamin
B3, vitamin B5, vitamin B12, folic acid, vitamin C, vitamin D and vitamin E. Suitable minerals include, but are not limited to selenium, chromium, calcium, iron, zinc, manganese and copper.
In another embodiment, the beverage composition may include protein. The beverage composition of the present invention may be used in the following situations:
(i) To reduce one or more symptoms of altitude sickness; (ii) To reduce one or more symptoms of dehydration;
(iii) To reduce the blood alcohol concentration of a subject;
(iv) To supplement or replace the meals of a subject undergoing medical treatment;
(v) To enhance the response of a subject to cancer therapy; (vi) To reduce or prevent cramps; and
(vii) To increase the stamina of a sportsman
In the above uses, those skilled in the art will realise that the amount of the beverage composition consumed, and the number of discreet consumptions per unit time will vary depending on the actual use to which the beverage is put, the condition of the subject who will consume the beverage, the subject's age, sex, weight and general health.
In another aspect, the present invention relates to a method of reducing one or more symptoms of altitude sickness in a subject comprising administration to said subject of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects. Altitude sickness is a pathological condition resulting from exposure to high altitudes. Altitude sickness typically occurs at heights above 2000 metres above sea level. Symptoms of altitude sickness include, but are not limited to: appetite loss, persistent rapid pulse, headache, nausea, fatigue, dizziness, weakness, insomnia, shortness of breath on exertion, peripheral edema, swollen hands and/or feet and/or face, and general malaise. Consumption of the composition of the first or fourth aspects effectively reduces one or more of the above symptoms of altitude sickness, even at altitudes above 6500 metres, hi one embodiment, the composition of the first; second, fourth or fifth to fourteenth aspects may be consumed in an amount of about 1 litre per day in order to reduce one or more symptoms of altitude sickness. It is to be noted however, that the amount of the composition required may vary depending on the altitude and location, the subject's age, sex, weight and prevailing health and fitness at the particular time. hi another aspect, the present invention relates to a method of reducing or preventing one or more symptoms of dehydration in a subject, comprising administration of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects.
Typical symptoms associated with dehydration include, but are not limited to: headache, decreased blood pressure, thirst, appetite loss, constipation, darkened urine, dizziness and dry mouth.
Consumption of the composition of the first, second, fourth or fifth to fourteenth aspects effectively reduces one or more symptoms of dehydration by replacing lost fluid and re-establishing electrolyte balance. In order to prevent symptoms of dehydration, the composition of the first or fourth aspects may be consumed before and during exercise, exertion or any other activity which leads to a depletion in the amount of fluid and electrolytes in the body. The composition may also be consumed by a subject already suffering from one or more symptoms of dehydration, thereby leading to a reduction in one or more of the symptoms thereof. When undertaking moderately strenuous exercise (for
example running at a speed of about 7 to 10 km/h for 1 hour), the composition of the first, second, fourth or fifth to fourteenth aspects may be consumed: (i) 250 niL to 350 mL prior to exercise; (ii) 50 mL to 100 mL every 30 minutes during exercise; (iii) 250 mL to 300 mL post exercise.
The above amounts will vary where more or less strenuous exercise is performed over a given period of time. In such a case, those skilled in the art will realise that greater or reduced amounts of the composition may be consumed at different time intervals depending on the subject's age, sex, weight and general health and fitness. A number of illnesses such as fever, severe diarrhea, vomiting and gastrointestinal disorders may lead to mild to severe dehydration. The beverage composition of the first or fourth aspect may be consumed by a subject suffering from an illness that results in dehydration in order to re-establish electrolyte balance and replace lost fluid.
The present inventor has also discovered that the beverage composition of the first, second or fourth aspect is useful in reducing the blood alcohol concentration in a subject.
Accordingly, in another aspect, the present invention relates to a method of reducing the blood alcohol concentration in a subject comprising administration of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects.
In one embodiment, the method involves the consumption by a subject of an amount of the composition of the first, second, fourth or fifth to fourteenth aspects, prior to consuming a first alcoholic drink, wherein the alcoholic drink comprises between approximately 1 and 3 standard drinks. For example, between approximately 150 mL and 600 mL, or between about 150 mL and 550 mL, or between about 150 mL and 500 mL, or between about 15OmL and about 450 mL, or between about 150 mL and about 400 mL, or between about 150 mL and about 350 mL, or between about 175 mL and about 350 mL, or between about 180 mL and about 300 mL, or between about 20OmL and about 300 mL, or between about 225 mL and about 275 mL, or between about 240 mL and about 260 mL, or between about 250 mL and about 300 mL of the composition may be consumed between about 15 minutes and 1 hour, or between about 20 minutes and 50 minutes, or between about 25 minutes and 45 minutes, or between about 25 minutes and 40 minutes, or between about 25 and 35 minutes, or about 30 minutes prior to consuming a first alcoholic drink. In
one embodiment, the composition of the first, second, fourth or fifth to fourteenth aspects may be added to the first alcoholic beverage.
After consumption of the first alcoholic drink and before consumption of a second alcoholic drink, the method may comprise consumption of between approximately 150 mL and 600 mL, or between about 150 mL and 550 mL, or between about 150 mL and 500 mL, or between about 15OmL and about 450 mL, or between about 150 mL and about 400 mL, or between about 150 mL and about 350 mL, or between about 175 mL and about 350 mL, or between about 180 mL and about 300 mL, or between about 20OmL and about 300 mL, or between about 225 mL and about 275 mL, or between about 240 mL and about 260 mL, of the composition. Consumption of the composition in this manner in the above amounts may be continued after consumption of each subsequent alcoholic drink, or alternatively after every second or third subsequent alcoholic drink.
In one embodiment, 250 mL of the composition may be consumed 30 minutes prior to consuming a first alcoholic drink (which comprises between approximately 1 and 3 standard drinks), followed by a further 250 mL of the composition after consuming the first alcoholic drink, and prior to consuming a second alcoholic drink. Consumption of the composition in this way leads to a reduction in the blood alcohol concentration of the subject as compared to drinking the same amount of water prior to, and after, the first alcoholic drink. In another embodiment, 250 mL to 300 mL of the composition may be consumed before drinking an alcoholic beverage, followed by a further 250 mL after consumption of a final alcoholic beverage.
Those skilled in the art will realise that the amount of the beverage composition consumed, and the number of discreet consumptions per alcoholic beverage will vary depending on the nature of the alcoholic beverage, as well as the age, sex, nationality, weight, general health of the subject, and also how regularly the subject consumes alcohol. The present invention also relates to a method for supplementing the meals or replacing the meals of a subject undergoing medical treatment comprising administration to said subject of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects.
The present invention further' relates to a method for enhancing the response of a
subject to cancer therapy, said method comprising administration to said subject of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects.
The present invention still further relates to the use of the composition of the first, second, fourth or fifth to fourteenth aspects as an adjunct to cancer therapy.
Subjects undergoing medical treatment such as cancer therapy (for example surgery, radiation therapy, chemotherapy, hormone therapy and/or biological therapy (immunotherapy)) often suffer from side effects including reduced appetite, nausea and vomiting. In certain circumstances, the subject is unable to consume an adequate amount of food, or in extreme cases no food, as a result of continuous vomiting. It has been found that the compositions of the first, second, fourth or fifth to fourteenth aspects may be used as an effective meal supplement in persons undergoing cancer therapy as the compositions do not cause vomiting. The compositions may also be used to replace meals where the subject is able to only consume minimal (if any) food. It is to be noted however that the use of the compositions as a meal supplement or meal replacement is not limited to subjects undergoing cancer therapy but may be used in a subject undergoing any type of medical therapy or intervention wherein the subject is unable to consume an adequate amount of food or no food at all.
A situation where a subject is unable to consume an adequate amount of food when undergoing cancer therapy is problematic for a number of reasons, one reason being that the response of the body to the cancer therapy may be less then optimum if the body is not receiving adequate nutrition, as a lack of nutrition can lead to suppression of the immune system. By providing the body with hydration, vitamins and electrolytes, the compositions of the first, second, fourth or fifth to fourteenth aspects may be used to enhance the body's response to cancer therapy by limiting suppression of the immune system that occurs as a result of a lack of nutrition or nutritional imbalance. This method may be of particular relevance where the subject is undergoing' a biological therapy wherein the goal is to stimulate the immune system to fight cancer. Accordingly, the compositions of the first, second, fourth or fifth to fourteenth aspects may form an integral part of cancer treatment methods when used in conjunction with known therapies, for example immunotherapy, chemotherapy and radiotherapy.
The compositions of the invention have been found to be particularly effective when administered to subjects undergoing therapy for cancers of the head and neck, throat cancer and esophageal cancer who experience trouble swallowing and/or taking solid food. The amount of the composition that may be given to the subject may be between about 500 mL and about 1.5 litres per day, or as required. In one embodiment, the amount of the composition given to a subject per day is about 1 litre. Additional vitamins and/or minerals may also be added to the compositions where appropriate. Those skilled in the art will realise that additional components included as we all as the amount of the composition consumed by a subject will vary depending on the age, sex, weight and general health of the subject, as well as the medical treatment that they are undergoing. hi a further aspect, the present invention provides a method for reducing or preventing cramps, said method comprising administration of an effective amount of the composition of the first, second, fourth or fifth to fourteenth aspects. In one embodiment, the cramp is a leg cramp. In one embodiment, in order to treat or prevent cramps, a subject may consume about 250 mL to 300 mL of the composition, or alternatively about 40 g to 50 g of the composition in a concentrate form (e.g. as a powder in accordance with the second aspect).
Examples
Example 1 - Use of the composition of the invention in reducing blood alcohol concentration
A test was conducted in order to demonstrate the ability of the composition of the invention to reduce blood alcohol concentration.
The test involved a total of 10 subjects' (a mixture of males and females) having an average age of 22 years, an average weight of 87 kg and an average height of 1.86 metres. The subjects took no anti-hangover medication during the test and were all healthy, having no history of serious illness.
The test method was as follows:
• To avoid stomach irritation, each test individual was given an equal amount of food containing a minimal amount of fat prior to consuming an alcoholic beverage.
• Each individual was given 250 mL of a composition (composition X) comprising
the following components in the amounts indicated per 25OmL of composition: (i) glucose 40 g;
(ϋ) sodium ions 125 mg; (iii) potassium ions 165 mg;
(iv) magnesium ions 40 mg;
(V) phosphate ions 250 mg;
(vi) vitamin C 120 mg; (vii) vitamin B6 5 mg; and (viii) citrate ions 450 mg. . "
Following this, within 30 minutes, each individual then consumed 2 x 100 mL of 56 proof Chinese liquor.
A second 250 mL of composition X was given to each individual after consumption of the first 100 mL of liquor.
Heart rate in a period of 30 seconds was measured every 10 minutes after the first 100 mL of liquor was consumed.
• A breath test for alcohol content was performed 10, 30, 50, 70 and 90 minutes after the first 100 mL of liquor was consumed.
• Seven days later, the above experiment was repeated wherein each individual was given water instead of composition X. The breath test results are depicted below in Table 1 and graphically represented in Figure 1. Heart rate measurements were also performed and are depicted in Table 2 and represented graphically in Figure 2.
TABLE 1 - Blood alcohol concentrations (mg/L) after a given time in individuals consuming a combination of (i) alcohol and composition X, and (ii) alcohol and water
10 minutes 30 minutes 50 minutes 70 minutes 90 minutes
Composition X / 82 .1 ±35.3 72.7 ± 27.0 107.7 ± 32. 6 100.9 ± 25. 7 93.1 ± 25.5 alcohol alcohol/water 85 .9 ± 28.4 128.4 ± 33.2* 141.6 ± 36. 1* 128.6 ± 27. 7* 121.8 ± 26.8* * Statistically significant (p > 0.05) after 30 minutes continue until end of experiment
TABLE 2 - Heart rate measurement performed every 10 minutes after first 100 mL of alcohol consumed
*Statisitical significance (p > 0.05)
Example 2 - Use of the composition of the invention as a food supplement
A subject suffering from nasopharyngeal carcinoma (nose cancer) was undergoing an intensive course of medical treatment that combined both chemotherapy and radiotherapy at the Queen Mary Hospital of Hong Kong. As a result of the medical treatment, the subject suffered severe throat pain which made eating and drinking extremely difficult and painful. Hot drinks in particular caused severe throat pain. In addition, the chemotherapy also affected the subject's appetite . and caused a considerable amount of vomiting. The treating physician recommended that the subject drink nutritional milk as a daily meal, however the milk also caused vomiting.
The subject was then given the composition of the second aspect in water as a meal supplement. The components included in the composition, and their amounts per 250 mL of the composition were as follows: (i) glucose 40 g; (ii) sodium ions 125 mg; . •
(iii) potassium ions 165 mg; (iv) magnesium ions 40 mg; (v) phosphate ions 250 mg;
(vi) vitamin C 250 mg; (vii) vitamin B6 10 mg; and
(viii) citrate ions 450 mg.
The subject was able to consume the above composition without vomiting, and the composition was successfully used throughout the subject's remaining treatment as the sole meal supplement. As a result, the subject experienced a significant decrease in the number of vomiting episodes, and benefited from the electrolytes, vitamins and carbohydrate
5 present in the composition.
Example 3 - Use of the composition of the invention in the treatment of symptoms associated with altitude sickness
The composition of the second aspect in water was consumed by a small group ofo professional mountaineers at 6500 metres whilst ascending Mt. Everest. The mountaineers found that following consumption of the composition, the symptoms associated with high altitude sickness were reduced. The components included in the composition, and their amounts per 250 mL of the composition were as follows:
(i) glucose 40 g; 5 (ii) sodium ions 125 mg;
(iii) potassium ions 165 mg; (iv) magnesium ions 40 mg; (v) phosphate ions 250 mg;
(vi) vitamin C 120 mg; Q (vii) vitamin B6 5 mg; and
(viii) citrate ions 450 mg.
This finding was recently confirmed by the inventor on a trip to the base camp of Mount Everest, which is at an altitude of 5200 meters.
The inventor has also found that consumption of the composition of the second5 aspect whilst travelling on the Xining to Lhasa railway, the majority of which is 3200 metres above sea level, resulted in no observed symptoms of altitude sickness. The components included in the composition, and their amounts per 250 mL of the composition were as follows:
(i) glucose 40 g; o (ii) sodium ions 125 mg;
(iii) potassium ions 165 mg; (iv) magnesium ions 40 mg;
(v) phosphate ions 250 nig;
(vi) vitamin C 120 mg;
(vii) vitamin B6 10 mg; and
(viii) citrate ions 450 mg
Claims
1. A method for supplementing the meals or replacing the meals of a subject undergoing medical treatment, said method comprising administration to said subject of an effective amount of a composition comprising: sodium ions, potassium ions, magnesium ions, phosphate ions, citrate ions, vitamin B6 and carbohydrate.
2. A method for enhancing the response of a subject to cancer therapy, said method comprising administration to said subject of an effective amount of a composition comprising sodium ions, potassium ions, magnesium ions, phosphate ions, citrate ions, vitamin B6 and carbohydrate.
3. A method for the treatment of cancer in a subject in need of said treatment,
■ said method comprising administering to said subject a composition comprising sodium ions, potassium ions, magnesium ions, phosphate ions, citrate ions, vitamin B6 and carbohydrate, together with chemotherapy and/or radiotherapy and/or biological therapy.
4. The method of any one of claims 1 to 3, wherein the composition is an aqueous beverage composition.
5. The method of claim 4, wherein the sodium ions are present in an amount between about 10 meq. and about 35 meq. per litre of the beverage composition.
6. The method of claim 4 or claim 5, wherein the potassium ions are present in an amount between about 5 meq. and about 30 meq. per litre of the beverage composition.
7. The method of any one of claims 4 to 6, wherein the magnesium ions are present in the composition in an amount between about 5 meq. and about 25 meq. per litre of the beverage composition.
8. The method of any one of claims 4 to 7, wherein the phosphate ions are present in an amount between about 1 meq. and about 55 meq. per litre of the beverage composition.
9. The method of any one of claims 4 to 8, wherein the citrate ions are present in an amount between about 0.1 meq. and about 45 meq. per litre of the beverage composition.
10. The method of any one of claims 4 to 9, wherein the vitamin B6 is present in an amount between about 0.1 mg and about 200 mg per litre of the beverage composition.
11. The method of any one of claims 4 to 10, wherein the carbohydrate is present in an amount between about 2% and about 20% by weight of the total beverage composition (w/w).
12. The method of any one of claims 4 to 11, wherein the carbohydrate is a monosaccharide, or a disacchari.de, or a mixture thereof.
13. The method of claim 12, wherein the monosaccharide is glucose, fructose, mannose, galactose, or a mixture thereof.
14. The method of any one of claims 4 to 13, wherein the composition further comprises vitamin C.
15. The method of claim 14, wherein the vitamin C is present in an amount between about 30 mg and about 2000 mg per litre of the beverage composition.
16. The method of any one of claims 4 to 15, wherein the pH of the composition is between about 3.0 and about 5.0.
17. The method of any one of claims 4 to 16, wherein the composition is in a dehydrated form selected from the group consisting of: a powder, granules or tablets.
18. The method of claim 4, wherein the composition comprises: between about 12 meq. and about 32 meq. per litre of sodium ions, between about 10 meq. and about 25 meq. per litre of potassium ions, between about 7 meq. and about 20 meq. per litre of magnesium ions, between about 5 meq. and 25 meq. per litre of phosphate ions, between 1 and 15 meq. per litre of citrate ions, between 20 mg and 40 mg per litre of vitamin B6 and between 10% and 20% glucose (w/w).
19. The method of claim 18, wherein the composition further comprises vitamin C in an amount between about 250 mg and about 1200 mg per litre.
20. The method of claim 18, wherein the composition comprises: about 22 meq. per litre of sodium ions, about 17 meq. per litre of potassium ions, about 13 meq. per litre of magnesium ions, about 10 meq. per litre of phosphate ions, about 5 meq. per litre of citrate ions, about 20 mg per litre of vitamin B6 and about 16% glucose (w/w).
21. The method of claim 18, wherein the composition comprises: about 22 meq. per litre of sodium ions, about 17 nieq. per litre of potassium ions, about 13 meq. per litre of magnesium ions, about 10 meq. per litre of phosphate ions, about 5 meq. per litre of citrate ions, about 40 mg per litre of vitamin B6 and about 16% glucose (w/w).
22. The method of claim 20 or claim 21, wherein the composition further comprises about 480 nag per litre of vitamin C.
23. The method of claim 20 or claim 21, wherein the composition further comprises about 1000 mg per litre of vitamin C.
5
24. The method of claim 4, wherein the composition comprises: between about
12 meq. and about 32 meq. per litre of sodium ions, between about 10 meq. and about 25 meq. per litre of potassium ions, between about 12 meq. and about 22 meq. per litre of magnesium ions, between about 10 meq. and about 20 meq. per litre of phosphate ions, between 0.1 meq. and about 8 meq. per litre of citrate ions, between about 50 mg and aboutQ 200 mg per litre of vitamin C, between about 10 and 80 mg per litre of vitamin B6, and between about 10% and about 20% glucose (w/w).
25. The method of claim 24, wherein the composition comprises: between about 17 meq. and about 27 meq. per litre of sodium ions, between about 13 meq. and about 21 meq. per litre of potassium ions, between about 13 meq. and about 21 meq. per litre ofs magnesium ions, between about 11 meq. and about 17 meq. per litre of phosphate ions, between about 0.25 meq. and about 5 meq. per litre of citrate ions, between about 100 mg and about 200 mg per litre of vitamin C, between about 20 and 60 mg per litre of vitamin B6, and between about 14% and about 18% glucose (w/w)
26. The method of claim 24, wherein the composition comprises: about 22 meq.Q per litre of sodium ions, about 17 meq. per litre of potassium ions, about 17 meq. per litre of magnesium ions, about 15 meq. per litre of phosphate ions, about 1 meq. per litre of citrate ions, about 160 mg per litre of vitamin C, about 40 mg per litre of vitamin B6, and about 16% glucose (w/w).
27. The method of claim 4, wherein the beverage composition is prepared by5 adding: sodium phosphate monobasic (400 to 550 mg), sodium chloride (60 to 80 mg), sodium citrate dihydrate (100 to 140 mg), potassium chloride (270 to 350 mg), magnesium sulfate (230 to 290 mg), vitamin C (30 to 50 mg), vitamin B6 (5 to 15 mg) and glucose (about 35 to 45 grams), to 250 mL of water, or other suitable liquid.
28. The method of claim 4, wherein the beverage composition is prepared byo adding: sodium phosphate monobasic (470.0 mg), sodium chloride (69.0 mg), sodium citrate dihydrate (120.0 mg), potassium chloride (318.0 mg), magnesium sulfate (260.0
mg), vitamin C (40.0 mg), vitamin B6 (10.0 mg) and glucose (about 40 grams), to 250 mL of water, or other suitable liquid.
29. The method of claim 4, wherein the beverage composition comprises: glucose (30 to 50 grams), sodium ions (100 mg to 150 mg), potassium ions (120 mg to 180 mg), magnesium ions (20 mg to 55 mg), phosphate ions (200 mg to 800 mg), vitamin C (80 mg to 1000 mg), vitamin B6 (1 mg to 20 mg) and citrate ions (200 mg to 900 mg), per 250 mL of composition.
30. The method of any one of claims 18 to 29, wherein the composition has a pH of between about 3.0 and 5.0.
31. The method of claim 30, wherein the composition has a pH of between about
3.4 and 3.8.
32. Use of a composition as defined in any one of claims 3 to 30 as an adjunct to cancer therapy.
33. The method of claim 1, wherein the medical treatment is cancer therapy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008229631A AU2008229631A1 (en) | 2007-03-16 | 2008-03-14 | Body fluid supplement compositions and their use in subjects undergoing medical treatment |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2007901392 | 2007-03-16 | ||
| AU2007901392A AU2007901392A0 (en) | 2007-03-16 | Body fluid supplement composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008113114A1 true WO2008113114A1 (en) | 2008-09-25 |
Family
ID=39765284
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/AU2008/000372 WO2008113115A1 (en) | 2007-03-16 | 2008-03-14 | Body fluid supplement composition and uses thereof |
| PCT/AU2008/000371 WO2008113114A1 (en) | 2007-03-16 | 2008-03-14 | Body fluid supplement compositions and their use in subjects undergoing medical treatment |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/AU2008/000372 WO2008113115A1 (en) | 2007-03-16 | 2008-03-14 | Body fluid supplement composition and uses thereof |
Country Status (2)
| Country | Link |
|---|---|
| AU (2) | AU2008229632A1 (en) |
| WO (2) | WO2008113115A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102949413A (en) * | 2012-06-08 | 2013-03-06 | 辽宁海思科制药有限公司 | Method for preparing invert sugar and electrolytes injection |
| JP2016042812A (en) * | 2014-08-21 | 2016-04-04 | アサヒ飲料株式会社 | Beverage composition and heatstroke preventive |
| US20200061111A1 (en) * | 2016-03-15 | 2020-02-27 | American University Of Beirut | Composition and use of macro-minerals to lower postprandial glycemic response and reduce body weight |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8293299B2 (en) | 2009-09-11 | 2012-10-23 | Kraft Foods Global Brands Llc | Containers and methods for dispensing multiple doses of a concentrated liquid, and shelf stable Concentrated liquids |
| US11013248B2 (en) | 2012-05-25 | 2021-05-25 | Kraft Foods Group Brands Llc | Shelf stable, concentrated, liquid flavorings and methods of preparing beverages with the concentrated liquid flavorings |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10203959A (en) * | 1997-01-23 | 1998-08-04 | Otsuka Pharmaceut Factory Inc | Infusion administered into central vein |
| US6039987A (en) * | 1998-01-14 | 2000-03-21 | Strahl; Robert Charles | Physical endurance drink and method of preventing cramping caused by strenuous bodily activity |
| US20040191388A1 (en) * | 2003-03-31 | 2004-09-30 | Cal Rifkin | Hydration beverage and method of delivering nutrients |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030099753A1 (en) * | 2001-11-20 | 2003-05-29 | Yang Baokang | Juice based beverage compositions |
-
2008
- 2008-03-14 AU AU2008229632A patent/AU2008229632A1/en not_active Abandoned
- 2008-03-14 WO PCT/AU2008/000372 patent/WO2008113115A1/en active Application Filing
- 2008-03-14 WO PCT/AU2008/000371 patent/WO2008113114A1/en active Application Filing
- 2008-03-14 AU AU2008229631A patent/AU2008229631A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10203959A (en) * | 1997-01-23 | 1998-08-04 | Otsuka Pharmaceut Factory Inc | Infusion administered into central vein |
| US6039987A (en) * | 1998-01-14 | 2000-03-21 | Strahl; Robert Charles | Physical endurance drink and method of preventing cramping caused by strenuous bodily activity |
| US20040191388A1 (en) * | 2003-03-31 | 2004-09-30 | Cal Rifkin | Hydration beverage and method of delivering nutrients |
Non-Patent Citations (4)
| Title |
|---|
| ABBOTT NUTRITION: "Information for Ensure products and Imagine Living Well with Cancer under Patient Education Materials", Retrieved from the Internet <URL:http://www.abbottnutrition.com/products/products.aspx?pid=222> * |
| ORAL IMPACT: "Nutritional Information and Product Features for Oral Impact products", Retrieved from the Internet <URL:http://www.impactinformation.com/products/oralimpact/nutritional.htm> * |
| PATENT ABSTRACTS OF JAPAN * |
| ULTIMA REPLENISHER: "Supplement Facts and Product Information for Ultima products", Retrieved from the Internet <URL:http://www.ultimareplenisher.com/ultimainfo.php> * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102949413A (en) * | 2012-06-08 | 2013-03-06 | 辽宁海思科制药有限公司 | Method for preparing invert sugar and electrolytes injection |
| JP2016042812A (en) * | 2014-08-21 | 2016-04-04 | アサヒ飲料株式会社 | Beverage composition and heatstroke preventive |
| US20200061111A1 (en) * | 2016-03-15 | 2020-02-27 | American University Of Beirut | Composition and use of macro-minerals to lower postprandial glycemic response and reduce body weight |
| US11141429B2 (en) * | 2016-03-15 | 2021-10-12 | American University Of Beirut | Composition and use of macro-minerals to lower postprandial glycemic response and reduce body weight |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008229631A1 (en) | 2008-09-25 |
| AU2008229632A1 (en) | 2008-09-25 |
| WO2008113115A1 (en) | 2008-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI478709B (en) | A useful oral or enteral composition for the recovery of bodily functions | |
| US7160565B2 (en) | Hydration beverage and method of delivering nutrients | |
| US20200281968A1 (en) | Physical optimization beverage | |
| ES2286238T3 (en) | COMPOSITION FOR REHYDRATION. | |
| WO2008014674A1 (en) | A nutritional and health-care edible potassium salt with wide purpose | |
| WO2008113114A1 (en) | Body fluid supplement compositions and their use in subjects undergoing medical treatment | |
| CN102994346A (en) | Base stock for preparing MACA wine | |
| WO2014093999A2 (en) | Alkaline drink | |
| TW200412863A (en) | Antioxidative compositions | |
| CN105054163A (en) | Vitamin absorbable jelly beverage and preparation method thereof | |
| CN103653113A (en) | Sea-buckthorn beverage | |
| US20030104107A1 (en) | Energy drink formula and method | |
| KR20110013685A (en) | A functional beverage comprising deep sea water, extract of fermented black ginger and extract of jujubae fructus as main ingredients | |
| US20060246200A1 (en) | Hydroxyapatite in aqueous solution for bone health | |
| JP5383244B2 (en) | Nutritional agent suitable for improving symptoms or nutritional status of cancer patients | |
| JP5527986B2 (en) | Pharmaceutical composition | |
| US20200054045A1 (en) | All-Natural Drink Composition for Synthesizing and Regenerating Adenosine Triphosphate (ATP) in Muscle Cells and Neurons, Repairing Exercise-Induced Muscle Fiber Damage, Repletion of Glycogen Stores in the Muscle and Liver, Enhancing Blood Flow to Tissue during Intense Exercise, and Preventing and Reducing Oxidative Damage to Tissues during Exercise with Minimal Gastrointestinal Disturbances | |
| KR20180002158A (en) | A composition for removing hangover comprising an herb extract including ginseng | |
| CN102784191A (en) | Phyllanthus emblica syrup composition and preparation method thereof | |
| US20200155636A1 (en) | Medicament and Beverage for Improving Joint and Bone Diseases | |
| CN112137112A (en) | Composite food for dispelling effects of alcohol and protecting liver and preparation method thereof | |
| CN109674842A (en) | A kind of ion Victoria C Chinese grooseberry composition and preparation method thereof | |
| RU2146529C1 (en) | Kit of antialcoholic agents | |
| CN1985850B (en) | Oral medicine composition for replenishing Ca, Mg and Fe and its preparing method and use | |
| JP2009533433A (en) | Compositions containing pyruvate alkyl esters and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08714418 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2008229631 Country of ref document: AU |
|
| ENP | Entry into the national phase |
Ref document number: 2008229631 Country of ref document: AU Date of ref document: 20080314 Kind code of ref document: A |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08714418 Country of ref document: EP Kind code of ref document: A1 |